US Pat. No. 10,714,723

SEPARATOR FOR A NON-AQUEOUS SECONDARY BATTERY, AND NON-AQUEOUS SECONDARY BATTERY

TEIJIN LIMITED, Osaka (J...

1. A separator for a non-aqueous secondary battery, comprising:a porous substrate having an average pore diameter of from 25 nm to 90 nm; and
a porous layer provided on one or both sides of the porous substrate and comprising a polyvinylidene fluoride resin and a filler,
the porous layer comprising a filler in an amount of from 53% by volume to 70% by volume with respect to a total solid content of the porous layer,
a weight average molecular weight of the polyvinylidene fluoride resin in the porous layer being 1,000,000 or more, and
a peel strength between the porous substrate and the porous layer being 0.3 N/12 mm or more.
US Pat. No. 10,709,085

LETTUCE VARIETY ‘80020-0911-007’

Bejo Zaden BV, Warmenhui...

1. A seed of lettuce variety ‘80020-09I1-007’, wherein a representative sample of seed of said variety was deposited under NCIMB Accession No. 42823.
US Pat. No. 10,711,392

PAD-STEAM BLEACHING METHOD FOR FABRIC BASED ON TBLC-ACTIVATED HYDROGEN PEROXIDE SYSTEM

Jiangnan University, Wux...

1. A method for pad-stream bleaching of fabric, which comprises:dipping a fabric in a solution system comprising an activator N-[4-(trialkylammoniummethylene)benzoyl]lactam chloride (TBLC), H2O2, and a weak base,
cold padding the fabric immediately following the dipping,
steaming the fabric for 2-6 min, and
washing the fabric in water,
wherein the concentration of TBLC is 25-100 g/L, and the weak base is sodium citrate.
US Pat. No. 10,709,086

CANOLA GERMPLASM EXHIBITING SEED COMPOSITIONAL ATTRIBUTES THAT DELIVER ENHANCED CANOLA MEAL NUTRITIONAL VALUE

Agrigenetics, Inc., Indi...

1. A dark canola seed characterized by a seed oil comprising at least 68% oleic acid (C18:1) and less than 3% linolenic acid (C18:3), wherein the dark canola seed is selected from the group consisting of CL065620 (ATCC No. PTA-11697), CL044864 (ATCC No. PTA-11696), CL121460H (ATCC No. PTA-11698), CL166102H (ATCC No. PTA-12570), and CL121466H (ATCC No. PTA-11699).
US Pat. No. 10,711,137

PIGMENT COMPOSITIONS CONTAINING CHLORINATED COPPER PHTHALOCYANINE PIGMENTS IN THE GAMMA CRYSTAL FORM

Sun Chemical Corporation,...

1. A chlorinated copper phthalocyanine pigment composition of a pure, or substantially pure, ? crystal form having an X-ray powder diffraction pattern in accordance with that shown in the FIGURE.
US Pat. No. 10,713,700

REPLACEMENT FOOTWEAR, PROCESS FOR ADDITION OF FOOTWEAR TO A USER'S FOOTWEAR COLLECTION, FOOTWEAR VENDING MACHINE, FOOTWEAR DISTRIBUTION PROCESS AND FOOTWEAR REPLACEMENT PROCESS

Grendene S.A., Sobral (B...

1. A shoe vending machine for selling an individual shoe to a user, comprising:a) a partitioned storage means, comprising at least one shoe storage partition;
b) a selection interface;
c) a payment means;
d) a delivery means for individually supplying a shoe stored in the partioned storage means to the user; and
e) a processing modulus comprising a means for communication with the internet, the processing modulus actuating the partitioned storage means, the selection interface, the payment means, and the delivery means;
wherein:
each of the at least one shoe storage partition having at least one shoe having at least one feature in common with at least one feature of at least one shoe of a user shoes collection;
the shoes stored in the partitioned storage means each having a geometry that adapts to both of the user's left foot and right foot;
the selection interface provides available shoe options for the shoes stored in the partitioned storage means, according to any physical feature of the shoe, wherein the selection interface comprises at least one of a shoe models catalog for pre-sale of a shoe ordered by the user, an interactive menu for customization of a shoe by the user, a means for communication with the user to inform the user that a requested shoe is ready for pickup, and a means to identify the shoes available in the partitioned storage means, wherein the means to identify the shoes available automatically issues a restock order from a predetermined minimum shoe stock limit in the partitioned storage means; and
the physical feature is selected from the group consisting of: size; shape; decorativeness; functionality; and material.
US Pat. No. 10,711,394

COMPOSITE HAVING PLANT FIBER TEXTILE AND FABRICATING METHOD THEREOF

AVIC COMPOSITE CORPORATIO...

1. A plant fiber reinforced biomass resin based foam laminate comprising:a biomass epoxy resin; and
a reinforcement body supporting the biomass epoxy resin, and including a plant fiber selected from ramie, flax, hemp, or jute plant fiber, the reinforcement body having a weight content of 40% to 60%, wherein the reinforcement body is impregnated into a first aqueous solution including a coupling agent for a coupling treatment and/or a second aqueous solution including a fire retardant for a fire retardant treatment,
the coupling agent includes a silane coupling agent or a potassium permanganate solution, the silane coupling agent being at least one selected from the group consisting of vinyltriethoxysilane, ?-amino propyltriethoxysilane, or ?-(2,3-epoxy-propoxy) propyltrimethoxysilane, and
the fire retardant includes a nitrogen phosphor based fire retardant,
wherein the biomass epoxy resin includes:
a biomass epoxy resin,
a Maleated rosin based epoxy resin curing agent, and
a micro-capsule foaming agent including a polylactic acid shell and an alkane enclosed in the polylactic acid shell, wherein the micro-capsule foaming agent expands by 50 to 100 times by volume after being heated up to 100° C. to 180° C.
US Pat. No. 10,709,088

HEMP CULTIVAR TM1

1. A plant of hemp cultivar TM1, wherein a representative sample of seed of said hemp cultivar was deposited under Accession No. NCMA 201903001, and wherein said plant produces female inflorescence, said inflorescence comprising a tetrahydrocannabinol (THC) content that is less than 0.3% as measured by high performance liquid chromatography (HPLC) and calculated based on dry weight of the inflorescence.
US Pat. No. 10,712,675

IMMERSION LIQUID, EXPOSURE APPARATUS, AND EXPOSURE PROCESS

ASML Netherlands B.V., V...

1. A lithographic apparatus comprising:a membrane impermeable to a liquid and permeable to a gas;
a liquid inlet configured to supply a flow of the liquid to a first side of the membrane;
a gas inlet configured to supply to a second side of the membrane a flow of the gas which diffuses through the membrane to dissolve in the liquid; and
a liquid confinement structure configured to at least partly confine at least part of the liquid having the dissolved gas to a space between a final element of a projection system of the lithographic apparatus and a radiation-sensitive substrate so as to have the liquid having the dissolved gas at least contact the substrate and so that the substrate is arranged to receive a beam of radiation from the projection system via the liquid having the dissolved gas in the space.
US Pat. No. 10,709,089

INTROGRESSION OF TWO YIELD QTLS IN CUCUMIS SATIVUS PLANTS

NUNHEMS B.V., Nunhem (NL...

1. A cultivated Cucumis sativus var. sativus plant, or plant cell, tissue, plant part or seed thereof, comprising an introgression fragment on chromosome 2 in homozygous or heterozygous form, wherein said introgression fragment is the fragment as found on chromosome 2 in seeds of which a representative sample has been deposited under accession number NCIMB 42545, wherein said introgression fragment comprises a Quantitative Trait Locus referred to as QTL2.1, which confers an increase in cucumber fruit yield, wherein said introgression fragment on chromosome 2 comprises at least one of the following markers:a) the CC or CT genotype for the Single Nucleotide Polymorphism marker SNP 01 at nucleotide 75 of SEQ ID NO: 1;
b) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 02 at nucleotide 75 of SEQ ID NO: 2;
c) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 03 at nucleotide 75 of SEQ ID NO: 3;
d) the TT or TC genotype for the Single Nucleotide Polymorphism marker SNP 04 at nucleotide 75 of SEQ ID NO: 4;
e) the TT or TC genotype for the Single Nucleotide Polymorphism marker SNP 05 at nucleotide 75 of SEQ ID NO: 5;
f) the CC or CT genotype for the Single Nucleotide Polymorphism marker SNP 06 at nucleotide 75 of SEQ ID NO: 6;
g) the CC or CT genotype for the Single Nucleotide Polymorphism marker SNP 07 at nucleotide 75 of SEQ ID NO: 7;
h) the AA or AG genotype for the Single Nucleotide Polymorphism marker SNP 08 at nucleotide 75 of SEQ ID NO: 8;
i) the TT or TG genotype for the Single Nucleotide Polymorphism marker SNP 09 at nucleotide 75 of SEQ ID NO: 9;
j) the TT or TG genotype for the Single Nucleotide Polymorphism marker SNP 10 at nucleotide 75 of SEQ ID NO: 10;
k) the GG or AG genotype for the Single Nucleotide Polymorphism marker SNP 11 at nucleotide 75 of SEQ ID NO: 11;
l) the GG or GT genotype for the Single Nucleotide Polymorphism marker SNP 12 at nucleotide 75 of SEQ ID NO: 12;
m) the CC or CA genotype for the Single Nucleotide Polymorphism marker SNP 13 at nucleotide 75 of SEQ ID NO: 13;
n) the AA or AG genotype for the Single Nucleotide Polymorphism marker SNP 14 at nucleotide 75 of SEQ ID NO: 14;
o) the CC or CT genotype for the Single Nucleotide Polymorphism marker SNP 15 at nucleotide 75 of SEQ ID NO: 15;
p) the AA or AC genotype for the Single Nucleotide Polymorphism marker SNP 16 at nucleotide 75 of SEQ ID NO: 16;
q) the TT or TC genotype for the Single Nucleotide Polymorphism marker SNP 17 at nucleotide 75 of SEQ ID NO: 17;
r) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 18 at nucleotide 75 of SEQ ID NO: 18;
s) the AA or AG genotype for the Single Nucleotide Polymorphism marker SNP 19 at nucleotide 75 of SEQ ID NO: 19;
t) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 20 at nucleotide 75 of SEQ ID NO: 20;
u) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 21 at nucleotide 75 of SEQ ID NO: 21;
v) the GG or GT genotype for the Single Nucleotide Polymorphism marker SNP 22 at nucleotide 75 of SEQ ID NO: 22;
w) the TT or TG genotype for the Single Nucleotide Polymorphism marker SNP 23 at nucleotide 75 of SEQ ID NO: 23;
x) the GG or GT genotype for the Single Nucleotide Polymorphism marker SNP 24 at nucleotide 75 of SEQ ID NO: 24;
y) the GG or GA genotype for the Single Nucleotide Polymorphism marker SNP 25 at nucleotide 75 of SEQ ID NO: 25; or
z) the CC or CA genotype for the Single Nucleotide Polymorphism marker SNP 26 at nucleotide 251 of SEQ ID NO: 26.
US Pat. No. 10,709,090

WHEAT VARIETY YW17M

PIONEER HI-BRED INTERNATI...

1. A plant, plant part, seed, or plant cell of wheat variety YW17M, representative seed of said variety having been deposited under ATCC accession number PTA-125188.
US Pat. No. 10,711,141

NICKEL FREE CONDUCTIVE FILLER

TRITON SYSTEMS, INC., Ch...

1. A composition comprising:an electrically conductive filler that comprises particles having a base substrate coated with a conductive coating; and
a polymer,
wherein the filler is loaded into the polymer at 25-60% by volume,
wherein the composition has a Delcom resistivity of <1 ohms/sq, and
wherein the base substrate is calcined petroleum coke and the conductive coating is tungsten.
US Pat. No. 10,714,729

CORE AND SEPARATOR ROLL

SUMITOMO CHEMICAL COMPANY...

1. A core for allowing a battery separator to be wound around an outer peripheral surface thereof, comprising two or more grooves in the outer peripheral surface, the two or more grooves extending in a direction intersecting a direction in which the battery separator is wound,the two or more grooves having a depth of 30 ?m or greater, and
the following condition (1) being satisfied:
N/D>0.0025  (1)
where D is an outer circumference in mm of the core and N is the number of the two or more grooves in the outer peripheral surface.
US Pat. No. 10,709,091

WHEAT VARIETY YW17P

PIONEER HI-BRED INTERNATI...

1. A plant, plant part, seed, or plant cell of wheat variety YW17P, representative seed of said variety having been deposited under ATCC accession number PTA-125189.
US Pat. No. 10,709,092

WHEAT VARIETY W082574K1

PIONEER HI-BRED INTERNATI...

1. A plant, plant part, seed, or plant cell of wheat variety W082574K1, representative seed of said variety having been deposited under ATCC accession number PTA-125190.
US Pat. No. 10,711,399

BLEACHING AND SHIVE REDUCTION PROCESS FOR NON-WOOD FIBERS

GPCP IP Holdings LLC, At...

1. A method for scouring and increasing the brightness of non-wood fibers, the method comprising:forming a mixture of non-wood fibers having a mean length of at least 7 millimeters (mm) into a fiber mat within a perforated basket arranged within a kier;
exposing the mixture to a scouring liquor and a scouring agent comprising oxygen gas to form a scouring mixture; and
scouring the scouring mixture in the perforated basket by radially circulating the scouring liquor, by a circulation pump, throughout the mixture to provide scoured fibers.
US Pat. No. 10,709,093

WHEAT VARIETY W090428N1

PIONEER HI-BRED INTERNATI...

1. A plant, plant part, seed, or plant cell of wheat variety W090428N1, representative seed of said variety having been deposited under ATCC accession number PTA-125195.
US Pat. No. 10,711,400

CARBON DIOXIDE SORBENTS AND STRUCTURES, METHODS OF USE, AND METHODS OF MAKING THEREOF

Arizona Board of Regents ...

1. A composite paper-like assembly comprising:at least a first and second layer including hydrophobic fibers; and
at least one of sorbent particles and a sorbent loaded paper sandwiched between the first and second layers.
US Pat. No. 10,709,094

PLANTS AND SEEDS OF CORN VARIETY CV793768

Monsanto Technology LLC, ...

1. A plant of corn variety CV793768, wherein representative seeds of corn variety CV793768 have been deposited under ATCC Accession No. PTA-126185.
US Pat. No. 10,714,733

BATTERY TERMINAL

YAZAKI CORPORATION, Toky...

1. A battery terminal comprising:an annular portion on which a post insertion hole to which a battery post is inserted and a slit that continues to the post insertion hole are formed;
a penetration plate that is arranged to penetrate through from one end portion of the annular portion to another end portion of the annular portion interposing the slit along a width direction that is a direction orthogonal to an axial direction and a direction of traversing the slit, where the axial direction is a direction that is parallel to a central axis of the battery post;
a retaining portion that is provided on one end portion of the penetration plate and prevents the penetration plate from coming off from the annular portion;
a fastening-member support portion provided on another end portion of the penetration plate;
a fastening member supported to be rotatable around the axial direction by the fastening-member support portion;
a fastened member that screws together with the fastening member; and
a pressing-force conversion member that is arranged in contact with the annular portion from the other end portion side of the penetration plate, and converts a tightening force in the axial direction that arises between the fastening member and the fastened member along with rotation of the fastening member around a rotational axis that is parallel to the axial direction into a pressing force in the width direction that presses the annular portion in a direction of reducing an interval of the slit of the annular portion out of the width direction, wherein
the annular portion is a pair of annular portions arranged to face each other along the axial direction, and are spaced apart from each other by a clearance extending therebetween,
the penetration plate is arranged to penetrate through the clearance of the pair of annular portions,
the pair of annular portions includes a first projecting portion that is provided to project along the axial direction from one of the pair of annular portions toward the penetration plate side, reduces the clearance of the pair of annular portions and contacts with the penetration plate.
US Pat. No. 10,709,095

MAIZE INBRED PH46AR

PIONEER Hl-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH46AR, representative seed of the variety having been deposited under ATCC accession number PTA-126643.
US Pat. No. 10,709,096

MAIZE INBRED PH48ZZ

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH48ZZ, representative seed of the variety having been deposited under ATCC accession number PTA-126649.
US Pat. No. 10,711,403

SHAPED TRAY OR PLATE OF FIBROUS MATERIAL AND A METHOD OF MANUFACTURING THE SAME

Stora Enso OYJ, Helsinki...

1. A method of manufacturing a shaped tray or plate of fibrous material, comprising the steps of:foam forming a web consisting of the steps of
providing a fibrous pulp, in which the fibres consist of at least 85 wt-% of softwood fibres having an average fibre length of at least 2.0 mm and at most 15 wt-% of broke having a fibre length of about 0.05 mm to 1.0 mm,
adding a surface active agent to the pulp and turning the pulp into a foamed suspension,
supplying the foamed suspension from a headbox to a forming fabric of a board machine to form a fibrous web, and
dewatering and/or drying the web to obtain a dried web having a compressibility in the thickness direction of at least 20%, and,
including the web, consiting of the dried web formed by the dewatering and/or drying step, as a layer in a board, which is turned to said tray or plate by thermopressing or deep-drawing.
US Pat. No. 10,709,097

MAIZE INBRED PH48G8

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH48G8, representative seed of the variety having been deposited under NCMA accession number 202004030.
US Pat. No. 10,709,098

MAIZE INBRED PH2SSR

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2SSR, representative seed of the variety having been deposited under NCMA accession number 202004007.
US Pat. No. 10,711,149

ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION FOR THREE-DIMENSIONAL MODEL SUPPORTING MATERIAL

KJ CHEMICALS CORPORATION,...

1. An active energy ray-curable resin composition for a three-dimensional molding support material, containing 1.0% by mass or more of an ionic monomer (A);wherein the active energy ray-curable resin composition is active energy ray-curable, and wherein the active energy ray-curable composition contains
1.0 to 30.0% by mass of the ionic monomer (A),
2.0 to 60.0% by mass of a non-ionic water-soluble monomer (B),
25.0 to 80.0% by mass of a non-polymerizable compound (C), and
0.1 to 5.0% by mass of a photopolymerization initiator (D),
with the proviso that the composition does not contain a urethane acrylamide having a polyethylene glycol skeleton.
US Pat. No. 10,709,099

MAIZE INBRED PH2TRF

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2TRF, representative seed of the variety having been deposited under NCMA accession number 202004037.
US Pat. No. 10,711,150

COLOR DEVELOPMENT WRITING COMPOSITIONS AND WRITING INSTRUMENTS

Crayola LLC, Easton, PA ...

1. An erasable writing composition for use with a substrate having a color-development coating, the composition comprising:at least one particulate filler including a clay;
at least one leuco dye;
one or more waxes chosen from the group consisting of soy wax, paraffin wax, and beeswax;
at least one thermoplastic binder material including high density polyethylene and low density polyethylene;
titanium dioxide; and
optionally at least one additive.
US Pat. No. 10,709,100

MAIZE INBRED PH41YN

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41YN, representative seed of the variety having been deposited under NCMA accession number 202004002.
US Pat. No. 10,711,151

COLORED LEAD OR COLORED CHALK, PENCIL CONTAINING A COLORED LEAD, AND PROCESS FOR PREPARING A COLORED LEAD OR COLORED CHALK

Faber-Castell AG, Stein ...

1. An erasable, sintered colored lead for writing, drawing and coloring implements or a colored chalk, comprising:a sintered lead or chalk base body formed from lead or chalk base material containing at least one binder with a proportion of from 4 to 17% by weight and at least one filler with a proportion of from 25 to 99% by weight;
at least one colorant;
at least one lubricant, said sintered lead or chalk base body being impregnated with said least one colorant and said at least one lubricant, said colorant being present in the colored lead or the colored chalk with a proportion of from 0.1 to 10% by weight; and
said at least one filler is selected from the group consisting of boron nitride, a mineral filler, kaolin, talc, calcium carbonate, and clay being present in said lead or chalk base material.
US Pat. No. 10,709,101

GARDEN BEAN VARIETY GREENBACK

Syngenta Crop Protection ...

1. A seed of bean cultivar Greenback, a representative sample of seed of said cultivar having been deposited under ATCC Accession No. PTA-125579.
US Pat. No. 10,709,102

TOMATO VARIETY NUN 09194 TOF

NUNHEMS B.V., Nunhem (NL...

1. A plant, plant part, or seed of tomato variety NUN 09194 TOF, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 43588.
US Pat. No. 10,711,153

COMPOSITION COMPRISING LIGNIN AND EPOXY COMPOUND FOR COATING AND METHOD FOR THE MANUFACTURING THEREOF AND USE THEREOF

Stora Enso OYJ, Helsinki...

1. A composition for coating, comprising unmodified lignin or modified lignin or both, a triethylenetriamine (TETA) catalyst, one or more epoxy-group containing compounds selected from the group consisting of epichlorohydrin (ECH), and poly(ethylene glycol) diglycidyl ether (PEGDGE), and combinations thereof, and a solvent selected from the group consisting of DMSO, MeOH, MeOH and water and combinations thereof, wherein the unmodified lignin is lignin that has not been modified through alkoxylation, ozonolysis, phenolation, or hydroxymethylation, and wherein the modified lignin is lignin that has been modified through alkoxylation, ozonolysis, or hydroxymethylation.
US Pat. No. 10,714,742

CATHODE ACTIVE MATERIAL INCLUDING LITHIUM TRANSITION METAL PHOSPHATE PARTICLES, PREPARATION METHOD THEREOF, AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME

LG Chem, Ltd., (KR)

1. A method of preparing a cathode active material, the method comprising:(i) preparing second secondary particles of lithium transition metal phosphate by primary spray drying and primary sintering a first spray solution including first lithium transition metal phosphate, a first carbon precursor, and water in a spray chamber; and
(ii) preparing first secondary particles of lithium transition metal phosphate respectively including the second secondary particle therein by secondary spray drying and secondary sintering a second spray solution including the second secondary particles, second lithium transition metal phosphate, a second carbon precursor, and water in a spray chamber,
wherein the first secondary particle is formed by agglomeration of two or more first primary particles and is porous, and the second secondary particle is formed by agglomeration of two or more second primary particles whereby a porous portion is created between the first primary particles and the second primary particles, and
wherein the cathode active material further comprises a carbon coating layer on the first primary particles and the second primary particles.
US Pat. No. 10,710,388

HEAT TRANSFER FILMS FOR THE DRY COATING OF SURFACES

BASF SE, Ludwigshafen (D...

1. A thermal transfer foil (1) comprising:a) a backing foil (2),
b) at least one layer (3) of coating material arranged on the backing foil (2),
c) at least one heat-sealable, polymeric adhesive layer (4),
where the layer of coating material is based on a non-aqueous, radiation-curable, liquid composition which comprises at least 60% by weight, based on the total weight of the composition, of curable constituents selected from organic oligomers which have ethylenically unsaturated double bonds and mixtures of said oligomers with monomers which have at least one ethylenically unsaturated double bond,
and where the heat-sealable polymeric adhesive layer (4) is based on at least two aqueous polymer dispersions, where at least one polymer dispersion comprises a UV-radiation-curable polymer in dispersed form, and where at least one other polymer dispersion comprises a self-crosslinking polymer in dispersed form.
US Pat. No. 10,709,619

FASTENING TAPE AND MECHANICAL FASTENER INCLUDING MICROPOROUS FILM

3M Innovative Properties ...

1. A mechanical fastener comprising:a microporous film having a thickness, an opaque, microporous region, and at least one see-through region of lower porosity within the opaque, microporous region, wherein the at least one see-through region of lower porosity extends through the thickness of the microporous film; and
mechanical fastening elements on at least one surface of the mechanical fastener, wherein the mechanical fastening elements are male fastening elements comprising upstanding posts having bases directly attached to the microporous film, or wherein the mechanical fastening elements are fibrous loops directly bonded to the microporous film.
US Pat. No. 10,711,157

COMPOSITION FOR WINDOW FILM, FLEXIBLE WINDOW FILM FORMED THEREFROM, AND FLEXIBLE DISPLAY DEVICE COMPRISING SAME

Samsung SDI Co., Ltd., Y...

1. A composition for window films, comprising:a silicone resin comprising a compound represented by Formula 1; a crosslinking agent; and an initiator:
(R1SiO3/2)x(SiO3/2-Q-SiO3/2)y(R2SiO3/2)z  
wherein in Formula 1, R1 and R2 are each independently an alicyclic epoxy group, an alicyclic epoxy group-containing functional group, a glycidyl group, or a glycidyl group-containing functional group;
Q is -A1-T-A2-,
A1 and A2 being each independently a single bond or a substituted or unsubstituted C1 to C5 alkylene group,
T being a mono- or polyalkylene oxide group, or an imide group-containing functional group; and
0
US Pat. No. 10,711,158

AQUEOUS SILICA SLURRY AND AMINE CARBOXYLIC ACID COMPOSITIONS FOR USE IN SHALLOW TRENCH ISOLATION AND METHODS OF USING THEM

Rohm and Haas Electronic ...

1. An aqueous chemical mechanical planarization polishing composition comprising an abrasive of one or more dispersions of elongated, bent or nodular colloidal silica particles which contain a cationic nitrogen atom, and one or more amine carboxylic acids having an isoelectric point (pI) below 5 selected from the group consisting of nicotinic acid, picolinic acid, glutamic acid, aspartic acid and pyridine acids, wherein the composition has a pH from 2 to 5, and, further wherein, the amount of the abrasive particles as solids, ranges from 0.01 to 20 wt. %, based on the total weight of the composition, and a cationic copolymer, wherein the cationic copolymer comprises a diallyldialkylamine salt having a cationic nitrogen and a sulfur dioxide repeating unit.
US Pat. No. 10,711,161

ADHESIVE SYSTEM WITH HIGHLY REACTIVE PRETREATMENT AGENT

SIKA TECHNOLOGY AG, Baar...

1. An adhesive system comprising:a) an adhesion promoter composition comprising:
i) at least one mercaptosilane MS, and
ii) at least one polysilane PS, and
iii) at least one transition metal complex K having substantially only unidentate ligands, and
iv) at least one nonalcoholic solvent L, and
b) an adhesive, wherein the adhesive is a one-component, moisture curing polyurethane adhesive containing a water-containing booster, and
the adhesive within an hour after application and storage at 23° C. and 50% relative humidity has a tensile shear strength of at least 3 MPa, measured according to ISO 4587, and/or within an hour after application and storage at 23° C. and 50% relative humidity has at least 50%, of the tensile shear strength attainable after application and storage for 7 days at 23° C. and 50% relative humidity, measured according to ISO 4587, and wherein
the composition contains an amount greater than 0% and at most 5 wt % of tertiary butyl alcohol.
US Pat. No. 10,711,674

PASSIVE NITROGEN OXIDE ADSORBER CATALYST

1. A catalyst comprising:a carrier substrate of length L,
passive nitrogen oxide adsorber material supported on the carrier substrate; and
a heating member that is positioned to heat the passive nitrogen oxide adsorber material at a time when exhaust flows over the passive nitrogen oxide adsorber material, wherein the heating member is a heating element supported on or integrated with the carrier substrate, and the passive nitrogen oxide adsorber material is a layer of passive nitrogen oxide adsorber material supported by the carrier substrate, and wherein the passive nitrogen oxide adsorber material is coated such that that the exhaust flow that is heated by the heating member travels over the passive nitrogen oxide adsorber material.
US Pat. No. 10,714,750

POROUS CARBON MATERIALS AND PRODUCTION PROCESS THEREOF, AND ADSORBENTS, MASKS, ADSORBING SHEETS AND CARRIERS

Sony Corporation, Tokyo ...

1. A porous carbon material comprising a material obtained from carbonization of a raw material including rice husk, the raw material having a silicon content of at least 5 wt %, the raw material is heat treated before carbonization, and the raw material is treated by an alkali treatment after carbonization to reduce the silicon content, the porous carbon material having a value of specific surface area of at least 10 m2/g as measured by the nitrogen BET method, a pore volume of at least 0.1 cm3/g as measured by the BJH method and MP method, and an R value of 1.5 or greater,wherein the porous carbon material includes mesopores having pore sizes from 2 nm to 50 nm and obtained from the alkali treatment of the raw material after carbonization, the porous carbon material further includes macropores and micropores,
the R value is expressed as R=B/A, the A referring to an intensity at an intersection between the baseline of a diffraction peak of the (002) plane as obtained based on powdery X-ray diffractometry of the porous carbon material and a perpendicular line downwardly drawn from the diffraction peak of the (002) plane, and the B referring to the intensity of the diffraction peak of the (002) plane.
US Pat. No. 10,711,163

REACTIVE 2-COMPONENT ADHESIVE FILM SYSTEM

TESA SE, Norderstedt (DE...

1. A reactive adhesive film system comprising a first solid-form reactive adhesive film comprising:a) an inert thermoplastic polyurethane film-forming matrix;
b) an at least one first reactive monomer selected from the group consisting of methyl methacrylate, methacrylic acid, cyclohexyl methacrylate, tetrahydrofurfuryl methacrylate, 2-phenoxyethyl methacrylate, di(ethylene glycol)methyl ether methacrylate, and ethylene glycol dimethacrylate; and
c) a first reagent selected from the group consisting of an initiator, a radical initiator, and an activator,and a second solid-form reactive adhesive film comprising:d) a polymeric film-forming matrix;
e) an at least one second reactive monomer or reactive resin; and
f) a second reagent selected from the group consisting of an initiator, a radical initiator, and an activator,wherein the first solid-form reactive adhesive film has pressure-sensitive adhesive properties.
US Pat. No. 10,711,164

PRESSURE-SENSITIVE ADHESIVE COMPRISING A POLYMER COMPONENT AND A SACCHARIDE COMPONENT AND METHOD FOR BONDING A FIRST SUBSTRATE TO A SECOND SUBSTRATE WITH SAME

TESA SE, Norderstedt (DE...

1. A pressure-sensitive adhesive comprising:at least 30 wt %, based on the weight of the pressure-sensitive adhesive, of a polymer component; and
up to 50 wt %, based on the weight of the pressure-sensitive adhesive, of a saccharide component,wherein the saccharide component is formed of:at least one first modified saccharide derivative derived from at least one first monosaccharide, at least one first disaccharide, at least one first oligosaccharide, or at least one first polysaccharide by modification of at least one hydroxyl group present in the at least one first monosaccharide, the at least one first disaccharide, the at least one first oligosaccharide, and the at least one first polysaccharide;
at least one second modified saccharide derivative derived from at least one second monosaccharide, at least one second disaccharide, at least one second oligosaccharide, or at least one second polysaccharide by modification of at least one hydroxyl group present in the at least one second monosaccharide, the at least one second disaccharide, the at least one second oligosaccharide, and the at least one second polysaccharide;and whereinthe ratio of the at least one first modified saccharide derivative to the at least one second modified saccharide derivative is between 1:9 and 1:1.
US Pat. No. 10,711,165

AQUEOUS ADHESIVE COMPOSITION

Rohm and Haas Company, C...

1. An aqueous adhesive composition comprising a polymer that comprises:(a) 80% to 95% by weight, based on the dry weight of said polymer, polymerized units of one or more alkyl (meth)acrylate monomer,
(b) 0.1% to 2.5% by weight, based on the dry weight of said polymer, polymerized units of acrylic acid or methacrylic acid or a mixture thereof,
(c) 2.0% to 15% by weight, based on the dry weight of said polymer, polymerized units of dibutyl itaconate, and
(d) 0% to 10% by weight, based on the dry weight of said polymer, polymerized units of one or more other monomer.
US Pat. No. 10,711,166

UV CURABLE ADHESIVES BASED ON ACRYLIC POLYMERS

1. A UV curable adhesive composition comprising:a) a UV curable acrylic polymer comprising at least one covalently bound UV-reactive group, wherein the at least one covalently bound UV-reactive group is benzophenone;
b) a cationic photoinitiator;
c) a photosensitizer; and
d) an unsaturated oligomer;wherein the UV curable acrylic polymer is built from mono-acrylic monomers having a formula of CH2?CH(R1)(COOR2), wherein R1 is H or CH3 and R2 is a branched or unbranched C1 to 20 alkyl chain.
US Pat. No. 10,709,118

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CONDITIONS AND DISEASES ASSOCIATED WITH MANNHEIMIA HAEMOLYTICA

Washington State Universi...

1. A genetically engineered ruminant animal having a genome comprising a nucleic acid sequence encoding a ruminant CD18 protein having a cleavable signal peptide with a helix-breaking amino acid residue at an amino acid positioned 5 residues upstream of the signal peptide cleavage site, wherein said nucleic acid sequence has been introduced by homozygous integration of the nucleic acid sequence into the endogenous CD18 gene thereby disrupting the expression of native CD18 having an intact signal peptide, wherein the mutant CD18 protein encoded by said nucleic acid sequence is expressed at least in the animal's leukocytes, and wherein the genetically engineered ruminant animal is resistant to, or less susceptible to, the effects of M. haemolytica, relative to a wild-type control animal.
US Pat. No. 10,711,169

THERMALLY ACTIVATABLE, FAST CURING ADHESIVE COATING

1. A thermally activatable adhesive compound to use in a method for producing a stack of metal sheets from glued together sheet metal components containing an aqueous dispersion comprising:100 parts by weight of an epoxy resin;
4 to 8 parts by weight of a latent curing agent;
4 to 10 parts by weight of a latent accelerator; and
water,
wherein the curing time is at most 5 seconds.
US Pat. No. 10,709,120

PEROMYSCUS ANIMAL MODEL FOR CANCER

University of South Carol...

1. An immunosuppressed Peromyscus californicus mouse comprising, an estrogen receptor negative ER (?) or estrogen receptor positive ER (+) xenograft human breast cancer cells admixed with human stromal fibroblasts, wherein the xenograft ER (?) or ER (+) breast cancer cells admixed with human stromal fibroblasts have been implanted in the Peromyscus californicus mouse, and wherein the mouse exhibits ER (?) or ER (+) breast tumor growth as a result of the xenograft implantation.
US Pat. No. 10,711,173

SALT TOLERANT FRICTION REDUCER

SOLVAY USA INC., Cranbur...

1. A friction reducing treatment fluid consisting of:a water-in-oil emulsion consisting of
an oil phase (0) and an aqueous phase (A) at an O/A ratio of from about 1:8 to about 10:1, wherein the oil phase is a continuous phase consisting of one or more inert hydrophobic liquids; wherein the aqueous phase is present as dispersed distinct particles in the oil phase and comprises water, a water soluble polymer, and surfactants; wherein the water soluble polymer consists of 30 to 55 weight percent of a non-ionic monomer wherein the nonionic monomer is acrylamide, 0.5 to 25 weight percent of a carboxylic acid containing monomer, wherein the carboxylic acid containing monomer is acrylic acid, 0 to 10 weight percent of a sulfonic acid containing monomer, and 40 to 60 weight percent of a cationic monomer, wherein the cationic monomer is acryloyloxyethyltrimethyl ammonium chloride (AETAC); and wherein the water soluble polymer is present in an amount from 5 to 40 weight percent of the water-in-oil emulsion;
an inverting surfactant; and,
optionally, at least one of a polymerization inhibitor or a salt.
US Pat. No. 10,710,407

RUBBER COMPOSITION FOR TIRE AND PNEUMATIC TIRE

The Yokohama Rubber Co., ...

1. A rubber composition for a tire, the rubber composition comprising:a diene rubber (A) and a microparticle (B);
a vinyl group content of the diene rubber (A) being from 5 to 35 mass %;
the microparticle (B) being a mercapto group-containing organic microparticle in which a crosslinkable oligomer or polymer (b1) is crosslinked;
an average particle size of the microparticle (B) being from 1 to 200 ?m; and
a content of the microparticle (B) being from 1 to 55 parts by mass per 100 parts by mass of the diene rubber (A).
US Pat. No. 10,710,410

POLYURETHANE FILLED TIRES

HUNTSMAN INTERNATIONAL LL...

4. A reaction system comprising:i) a polyisocyanate composition having a free NCO-value of 15-25% by weight comprising an isocyanate-terminated prepolymer which is the reaction product of an excess of an organic polyisocyanate and a polyether polyol having an average nominal hydroxyl functionality of 2-6, a number average molecular weight of 2000-6000 and an oxyethylene content of 20-35% by weight, wherein at least 50% of the oxyethylene groups are present at the end of the polyether polyol;
ii) a polymer polyetherpolyol wherein the polymer polyetherpolyol consists of (a) at least one polyetherpolyol having a maximum oxyethylene content of 20% by weight calculated on the total weight of the at least one polyetherpolyol, (b) a second polyetherpolyol having an oxyethylene content of 10-20% by weight calculated on the total weight of the second polyetherpolyol, and (c) solid particles, and wherein a mixture of (a) and (b) has a weighted average molecular weight in the range of 4000-7000 and wherein the amount of solid particles is in the range of 15-35 wt % calculated on the total weight of the polymer polyetherpolyol;
iii) at least one of a chain extender and cross-linker;
iv) a catalyst; and
v) a blowing agent,
and wherein the reaction system, upon reacting, provides a cellular polyurethane elastomeric material having the following properties: a shore A hardness according to ASTM D2240 of at least 45 and lower than 85; a compression set at room temperature lower than 10% and at 70° C. lower than 40% according to ASTM D395; and a ball rebound according to ASTM D3574 of at least 40%.
US Pat. No. 10,710,155

MIXED POWDER FOR POWDER METALLURGY, SINTERED BODY, AND METHOD OF MANUFACTURING SINTERED BODY

JFE STEEL CORPORATION, C...

1. A mixed powder for powder metallurgy, comprising:a partially diffusion alloyed steel powder in which Mo diffusionally adheres to a particle surface of an iron-based powder;
a Cu powder; and
a graphite powder,
wherein the mixed powder for powder metallurgy has a chemical composition containing Mo in an amount of 0.2 mass % to 1.5 mass %, Cu in an amount of 0.5 mass % to 4.0 mass %, and C in an amount of 0.1 mass % to 1.0 mass %, with the balance consisting of Fe and inevitable impurities, and
the partially diffusion alloyed steel powder has: a mean particle diameter of 30 ?m to 120 ?m; a specific surface area of less than 0.10 m2/g; and a circularity of particles thereof with a diameter in a range from 50 ?m to 100 ?m of 0.65 or less.
US Pat. No. 10,709,129

SYNERGISTIC COMBINATION OF BIS-(3-AMINOPROPYL)DODECYLAMINE AND SORBIC ACID

DUPONT SPECIALTY PRODUCTS...

1. A synergistic antimicrobial composition comprising bis-(3-aminopropyl)dodecylamine and sorbic acid.
US Pat. No. 10,710,925

BOROSILICATE GLASS FOR PHARMACEUTICAL CONTAINER

NIPPON ELECTRIC GLASS CO....

1. A borosilicate glass for a pharmaceutical container, comprising:SiO2, Al2O3, B2O3, and R2O, wherein R is selected from the group consisting of Li, Na, and K, as essential components,
wherein a content of CaO is equal to or greater than 0 and smaller than 0.5 mol %,
wherein a value of (Na2O+K2O+Li2O Al2O3)/B2O3 is 0.315 to 0.350 in terms of a molar ratio,
wherein BaO is not substantially included, and
wherein a value of (SiO2+Al2O3+B2O3)/(Na2O+K2O+Li2O+CaO+MgO) is 10 to 12 in terms of a molar ratio.
US Pat. No. 10,709,131

GENERATION OF PEROXYFORMIC ACID THROUGH POLYHYDRIC ALCOHOL FORMATE

Ecolab USA Inc., Saint P...

1. A method of treating teats of lactating animals comprising:contacting a teat surface with an effective amount of a disinfectant composition comprising peroxyformic acid for a sufficient time to disinfect said surface,
wherein the peroxyformic acid is formed by the method comprising: combining a first reagent that comprises an ester of a polyhydric alcohol and formic acid, and a second reagent that comprises hydrogen peroxide or that comprises a substance that generates hydrogen peroxide when in contact with a liquid, wherein
1) said first reagent and said second reagent are kept separately prior to use, and when it is time to generate peroxyformic acid, said first reagent and said second reagent are configured to be contacted with each other to form a liquid that comprises peroxyformic acid, wherein said pH of the formed liquid becomes about 8 or lower within about 1 minute after the contacting between said first reagent and said second reagent; or
2) said second reagent comprises a substance that generates hydrogen peroxide when in contact with a liquid, said first reagent and said second reagent are comprised in a solid composition, and when it is time to generate peroxyformic acid, said solid composition is configured to be contacted with a liquid to form a liquid that comprises peroxyformic acid, wherein said pH of the formed liquid becomes about 8 or lower within about 1 minute after the contacting between said solid composition and said liquid.
US Pat. No. 10,709,644

ORAL CARE PRODUCTS AND METHODS OF USE AND MANUFACTURE THEROF

Colgate-Palmolive Company...

1. A lubricating dual-phase mouthwash for the treatment or alleviation of dry mouth comprising:a hydrophilic phase;
a hydrophobic phase comprising at least two oils, wherein the oils comprise coconut oil in an amount of from 0.1%-1% by weight of the composition and mineral oil in an amount of from 5%-15% by weight of the composition, wherein the coconut oil is dispersed in the mineral oil, wherein the hydrophobic phase is from 5% to 20% of the composition by volume;
a hydrotrope component, wherein the hydrotrope component comprises glycerin and sorbitol;
wherein the mouthwash is prepared by a process comprising the steps of:
a) dispersing coconut oil in a hydrophobic composition comprising an oil to form a mixture; and
b) combining the mixture with the hydrophilic phase and the hydrotrope component, and
wherein the composition delivers a lubricating effect to the oral cavity.
US Pat. No. 10,710,158

SLURRY USED FOR A FOOD PACKAGING SUBSTANCE AND METHOD OF PREPARATION INCLUDING THE FOOD PACKAGING STRUCTURE AND SUBSTANCE

Tsung-Chih Huang, Zhubei...

1. A method of making a food packaging substance, comprising:providing a composition for preparing a polyester and a slurry, wherein the slurry includes ethylene glycol, DI water, and W18O49-based tungsten oxide particles that have an average particle size of less than 100 nm, and wherein, based on 100 wt. % of the slurry, the W18O49-based tungsten oxide particles containing an amount of 18 wt. % to 28 wt. %,
conducting esterification and polymerization of the composition, and
adding the slurry to the composition during one of the esterification and polymerization of the composition, wherein the step of adding the slurry forms the food packaging substance that includes the polyester and the W18O49-based tungsten oxide particles with an average particle size of less than 100 nm.
US Pat. No. 10,709,132

MICROBICIDAL COMPOSITION

DUPONT SPECIALTY PRODUCTS...

1. A synergistic microbicidal composition comprising: (a) 4,4-dimethyloxazolidine; and (b) pine oil.
US Pat. No. 10,709,645

MICROCAPSULES

BASF SE, (DE) BASF Grenz...

1. A microcapsule comprising a capsule core comprising a core material and a capsule shell wherein the capsule shell consists of a core surrounding layer consisting of a polyvinyl alcohol and an adjacent layer consisting of a polyoxazoline;wherein the core material is one or more oil soluble UV filters (o) selected from the group consisting of
(o1) p-amino benzoic acid derivatives,
(o2) salicyl acid derivatives,
(o3) benzophenone derivatives,
(o4) dibenzoylmethane derivatives,
(o5) diphenylacrylates,
(o6) 3-imidazol-4-yl-acryl acid and their esters;
(o7) benzofurane derivatives;
(o8) polymeric UV filters;
(o9) cinnamic acid derivatives;
(o10) camphor derivatives;
(o11) hydroxyphenyl triazine derivates;
(o12) benzotriazole derivatives;
(o13) trianilino-s-triazine derivatives;
(o14) menthyl o-aminobenzoates;
(o15) homosalates;
(o16) benzylidene malonates;
(o17) merocyaninederivatives;
(o18) phenylene bis diphenyl triazines;
(o19) imidazoline derivatives; and
(o20) diaryl butadiene derivatives.
US Pat. No. 10,714,771

BELOW FREEZING START-UP METHOD FOR FUEL CELL SYSTEM

Daimler AG, Stuggart (DE...

1. A method for starting up a fuel cell system from a starting temperature below 0° C., the system comprising a fuel cell stack comprising a series stack of solid polymer electrolyte fuel cells, the cathodes in the fuel cells comprising an ORR catalyst, the anodes in the fuel cells comprising an HOR catalyst and an OER catalyst wherein the OER catalyst is different from the HOR catalyst, and the fuel cell stack characterized by a maximum output OER/ORR current density wherein the maximum OER/ORR current density is the maximum current density output from the fuel cell stack when operating without a supply of fuel and is a function of fuel cell temperature and relative humidity in the fuel cells, the method comprising:from the beginning of the starting up until the fuel cell temperature reaches 0° C., drawing a current from the fuel cell stack such that the current density drawn is less than the maximum OER/ORR current density at the fuel cell temperature and at maximum water content.
US Pat. No. 10,709,646

ORAL CARE WHITENING COMPOSITIONS

Colgate-Palmolive Company...

1. An oral care whitening composition comprising a non-aqueous phase comprising:a peroxysulfate whitening agent comprising potassium peroxymonosulfate;
a hydrophobic base comprising a silicone adhesive and a silicone polymer present in a weight ratio ranging from about 70:30 to about 50:50, wherein the hydrophobic base is present at a concentration of 20 to 80%, by weight of the composition; and
at least one hydrophilic polymer comprising:a block copolymer of ethylene oxide and propylene oxide, wherein the ethylene oxide constituent comprises from 65% to 75% by weight of the copolymer;a mixture of soluble linear polymers and insoluble cross-linked polymers, selected from a mixture of linear polyvinylpolypyrrolidone (PVP) and cross-linked PVP; andwherein the non-aqueous phase is substantially anhydrous.
US Pat. No. 10,711,184

DOPED SEMICONDUCTORS AND METHODS OF MAKING THE SAME

Alliance for Sustainable ...

1. A composition comprising:a first element;
a second element;
a third element;
a ligand; and
an anion, wherein:
the first element and the second element form a nanocrystal comprising a surface and a crystal lattice,
the nanocrystal further comprises at least one of lead selenide, lead sulfide, lead telluride, cadmium sulfide, cadmium selenide, cadmium telluride, indium phosphide, indium nitride, indium arsenide, indium antimonide, zinc sulfide, zinc selenide, zinc telluride, mercury sulfide, mercury selenide, or mercury telluride,
a first portion of the third element covers at least a portion of the surface in the form of a layer,
a second portion of the third element is incorporated into the crystal lattice, and
the ligand and the anion are ionically bound to at least one of the second element or the first portion of the third element.
US Pat. No. 10,709,647

SKIN CARE COMPOSITION COMPRISING TURBOSTRATIC BORON NITRIDE

Conopco, Inc., Englewood...

1. A personal care composition comprising:a) turbostratic boron nitride;
b) porous silica having a specific surface area of higher than 300 m2/g; and
c) a cosmetically acceptable carrier;
wherein oxygen content is from 1 to 3% by mole of the turbostratic boron.
US Pat. No. 10,714,775

FUEL CELL SYSTEM

TOYOTA JIDOSHA KABUSHIKI ...

1. A fuel cell system including a fuel cell that outputs electrical energy through an electrochemical reaction between fuel gas and oxidant gas, the fuel cell being a polymer electrolyte fuel cell, the fuel cell system comprising:a low-frequency superimposition section configured to superimpose a low-frequency signal on the fuel cell, the low-frequency signal being at a low frequency that is equal to or lower than 200 Hz;
an impedance computation section configured to compute impedance of the fuel cell at a time when the low-frequency superimposition section superimposes the low-frequency signal on the fuel cell;
a diagnosing section configured to diagnose a degree of dryness inside the fuel cell on the basis of the impedance computed by the impedance computation section; and
an oxidant gas amount adjustment section configured to adjust an amount of the oxidant gas in the fuel cell, wherein
the diagnosing section is configured to diagnose the degree of dryness inside the fuel cell on the basis of the impedance only when the oxidant gas amount adjustment section has adjusted the amount of the oxidant gas to be equal to or smaller than a specified reference gas amount.
US Pat. No. 10,709,137

MOLD REMOVER AND SEALER WITH OPTIONAL TRACER AND METHOD

1. A liquid mold remover and sealer comprising water, a surfactant, sodium hypochlorite, colloidal copper, and one or more alcohols.
US Pat. No. 10,709,907

TAURINE AND ALOE SYNERGISTIC ANTI-IRRITANT COMPOSITIONS AND METHODS

Colgate-Palmolive Company...

1. A personal care composition comprising about 2 to 40 weight percent of an active ingredient, wherein the active ingredient is a metal-containing antiperspirant active ingredient, in combination with aloe extract and taurine, wherein a total amount of aloe extract is 0.01 to 5 weight percent, and a total amount of taurine is 0.01 to 5 weight percent, in an acceptable carrier, all based on the total weight of the composition, wherein the aloe extract and taurine are present in a synergistic combination to reduce cytotoxicity and irritation/inflammation effects of the metal-containing antiperspirant active ingredient.
US Pat. No. 10,709,138

HERBICIDAL AGRICHEMICAL COMPOSITION AND HERBICIDAL METHOD USING SAME

KUMIAI CHEMICAL INDUSTRY ...

1. A herbicidal composition, comprising:a herbicidal active ingredient comprising fenquinotrione and having a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitory action; and
an inorganic phosphorus compound comprising a phosphorus oxoacid or an agriculturally acceptable salt thereof,
wherein the composition, combining the herbicidal active ingredient and the inorganic phosphorus compound, has increased HPPD inhibitory herbicidal activity relative to a composition having only one of the herbicidal active ingredient or the inorganic phosphorus compound.
US Pat. No. 10,709,651

COSMETIC COMPOSITION CONTAINING ACYL BASIC AMINO ACID DERIVATIVE AND INORGANIC POWDER

AJINOMOTO CO., INC., Tok...

1. A dry surface-treated powder, comprising:(A) at least one compound selected from the group consisting bis(N?- lauroyl-L-lysine)sebacoyl amide, a salt of bis(N?-lauroyl-L-lysine)sebacoyl amide, bis(N?-octanoyl-L-lysine)sebacoyl amide, and a salt of bis(N?-octanoyl-L-lysine)sebacoyl amide;
coated on
(B) at least one kind of inorganic powder selected from the group consisting of talc, mica, sericite, iron oxide, titanium oxide, zinc oxide, and aluminum hydroxide,
wherein said (A) and said (B) are present in a weight ratio, weight of (A)/weight of (B), in a range of 1/200 to 1/5.
US Pat. No. 10,709,908

SULFATE-FREE FORMULATIONS FOR SKIN CLEANSING

RHODIA OPERATIONS, Auber...

1. A liquid cleansing composition consisting of:a. from about 20% to about 40% by weight of an anionic surfactant selected from the group consisting of sodium cocoyl glycinate, sodium methyl cocoyl taurate, and sodium lauryl glycinate;
b. from about 10% to about 30% by weight of an amphoacetate; and
c. from about 10% to about 30% by weight of a sultaine;
d. from about 0.5% to about 2% by weight of a fatty acid;
e. optionally one or more members selected from the group consisting of water, structuring agents, vitamins, botanical extracts, moisturizers, emollients, preservatives, exfoliating agents, oils, and fragrances,wherein the amounts are based upon the total weight of the composition and the composition is free of anionic alkyl sulfates and alkyl ether sulfates.
US Pat. No. 10,709,139

INSECTICIDAL COMPOSITIONS AND METHODS OF USING THE SAME

CLARKE MOSQUITO CONTROL P...

1. A method for killing mosquitoes by contacting a population of mosquitoes with a composition comprising: i. a pyrethrin selected from the group consisting of Jasmolin-I, Cinerin-I, Pyrethrin-I, Jasmolin-II, Cinerin-II, Pyrethrin-II, and a combination thereof, and ii. a carvone selected from the group consisting of R-carvone, S-carvone, and a combination thereof, wherein the R-carvone and the S-carvone are isolated, synthetic, or a combination thereof, and wherein the composition effectively kills the mosquitoes.
US Pat. No. 10,711,190

CORE-SHELL PARTICLES, METHOD FOR PRODUCING CORE-SHELL PARTICLES, AND FILM

FUJIFILM Corporation, To...

1. Core-shell particles comprising:a core containing a Group III element and a Group V element; and
a shell covering at least a portion of the surface of the core and containing a Group II element and a Group VI element,
wherein the proportion of the peak intensity ratio of the Group II element with respect to the peak intensity ratio of the Group III element as measured by X-ray photoelectron spectroscopy analysis is from 0.26 to 0.41.
US Pat. No. 10,709,140

METHODS AND PRODUCTS FOR REDUCING THE POPULATION SIZE OF PAPILIO DEMOLEUS L. (PAPILIONIDAE)

The University of The Wes...

23. A method of controlling the population size of Papilio demoleus comprising: applying directly to Papilio demoleus a toxic extract derived from a non-host plant.
US Pat. No. 10,709,654

SYNERGISTIC PHOTOPROTECTIVE COMPOSITIONS

EDGEWELL PERSONAL CARE BR...

1. A photoprotective composition, comprising:at least one photoactive agent present in an amount of about 0.1 to about 40 wt. %, based on a total weight of the photoprotective composition;
a synergistic combination of polymers present in an amount of about 0.1 to about 15 wt. %, based on a total weight of the photoprotective composition comprising:
0.1 to 5 wt. % of an alkyl-dimethicone having a hydrophilic group, an alkyl-PPG dimethicone, an alkyl-PEG dimethicone, or combinations thereof;
0.1 to 5 wt. % of a polymer with ester linkages comprising polyglyceryl stearate/isostearate dilinoleate crosspolymer in semi-solid form, polyglyceryl stearate/isostearate dilinoleate crosspolymer in liquid form, polyglyceryl stearate/isostearate dilinoleate crosspolymer in solid form or combinations thereof; and
0.1 to 5 wt. % of phenylisopropyl dimethicone; and
0.1 to 5 wt. % of an abietic acid ester,wherein said photoprotective composition is an anhydrous, single phase, homogenous composition that forms a substantially complete film on a dry or wet substrate, andwherein said synergistic combination of polymers increases a UVR absorbance of the photoprotective composition in comparison with a photoprotective composition without said synergistic combination of polymers.
US Pat. No. 10,709,655

PEPTIDE COMPOSITION AND RESPECTIVE USES

UNIVERSIDADE DO MINHO, B...

1. A peptide composition for hair treatment comprising at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines, and at least one dermatologically adequate excipient, wherein the at least one peptide comprises at least 90% sequence identity to one of the sequences selected from the group consisting of: SEQ.ID NO:75, SEQ.ID NO:412, and SEQ.ID NO:1131, and wherein the at least one dermatologically adequate excipient comprises at least one emulsifier selected from the group consisting of: C10-15 pareth-(2,4,6,8) phosphate, ceteareth-(4-60), cocamidopropyl lauryl ether, deceth-(3-10), DIPA-hydrogenated cocoate, dipentaerythrityl hydroxystearate, dipentaerythrityl hydroxyisostearate, dipentaerythrityl hexacaprate/caprylate, dodoxynol-(5,6,7,9,12), nonoxynol-(1-35), octoxynol-(1-70) and Octyldodeceth-(2,5,16,20,25).
US Pat. No. 10,709,656

EMULSION COSMETIC COMPOSITION CONTAINING CERAMIDE AND METHOD FOR PREPARING SAME

AMOREPACIFIC CORPORATION,...

1. An oil-in-water emulsion cosmetic composition comprising amphiphilic anisotropic powder, an oil-phase ceramide contained in an oil phase, and ceramide particles contained in an aqueous phase,wherein the amphiphilic anisotropic powder comprises a first hydrophilic polymer spheroid and a second hydrophobic polymer spheroid,
the first polymer spheroid and the second polymer spheroid are bound to each other with a structure in which one polymer spheroid at least partially penetrates into the other polymer spheroid,
the first polymer spheroid has a core-shell structure, the shell has a functional group, and
wherein the ceramide particles are formed as a crystalline phase in which a ceramide in the aqueous phase is surrounded with the amphiphilic anisotropic powder, and wherein the ceramide particles have an average particle diameter of 5-200 ?m.
US Pat. No. 10,710,938

METHODS OF MOBILIZING SOIL PHOSPHORUS WITH A SYNERGISTIC BACTERIAL CONSORTIA

COLORADO STATE UNIVERSITY...

1. A method for enhancing the rate at which organic phosphorus is converted to orthophosphate comprising:contacting a medium containing organic phosphorus with a composition comprising bacterial species Comamonas testosteroni and Pseudomonas putida;
allowing the bacterial species to convert the organic phosphorus to orthophosphate; and
allowing the bacterial species to release the orthophosphate into the medium, wherein the amount of orthophosphate in the medium is greater than the amount of orthophosphate in the same medium that is not contacted with the composition; and thereby enhancing the rate at which organic phosphorus is converted to orthophosphate.
US Pat. No. 10,709,657

HAIR-STYLING COMPOSITIONS COMPRISING A COMBINATION OF LATEX FILM-FORMING POLYMERS

6. A method for styling hair comprising applying to hair the hair styling composition of claim 1.
US Pat. No. 10,709,658

COMPOSITIONS AND METHODS FOR TREATING HAIR

1. A method of styling the hair, said method comprising applying to the hair a composition comprising:a) latex polymer A, wherein latex polymer A is Polyurethane-34, and
b) latex polymer B, wherein latex polymer B is Acrylates copolymer;
wherein the total combined amount of latex polymers A and B ranges from about 0.1% to about 30% by weight, relative to the weight of the composition; and
wherein the weight ratio of latex polymers A:B ranges from about 10:1 to about 1:10.
US Pat. No. 10,714,784

SECONDARY BATTERY AND ELECTRONIC DEVICE

Semiconductor Energy Labo...

8. A secondary battery comprising a film,wherein the film has a first region with a first pattern of depressions or projections and a second region different from the first region,
wherein the secondary battery has flexibility,
wherein the secondary battery is a multi-stable flexible secondary battery having at least a first stable condition and a second stable condition,
wherein the first stable condition is fixed while being bent,
wherein the second stable condition is different from the first stable condition, and
wherein the secondary battery deforms repeatedly between the first stable condition and the second stable condition.
US Pat. No. 10,709,146

CMP-CONTAINING, HIGH PROTEIN DENATURED WHEY PROTEIN COMPOSITIONS, PRODUCTS CONTAINING THEM, AND USES THEREOF

ARLA FOODS AMBA, Viby J ...

1. A denatured whey protein composition containing:a total amount of protein of at least 70% (w/w) on a dry weight basis,
a total amount of CMP of at least 16% (w/w) relative to the total amount of protein,
insoluble whey protein particles having a particle size in the range of 1-10 microns, where the amount of said insoluble whey protein particles is in the range of 50-84% (w/w) relative to the total amount of protein.
US Pat. No. 10,709,659

COMPOSITION AND METHODS FOR HAIR REGROWTH

NUTRACEUTICAL WELLNESS IN...

1. A composition for promoting hair growth and reducing hair loss, comprising from 100 to 1000 mg of an extract of Curcuma longa, from 100 mg to 1000 mg of an extract of the roots and leaves of Withania somnifera, at least 200 mg of saw palmetto extract, low molecular weight collagen, hyaluronic acid and a pharmaceutically suitable encapsulating material.
US Pat. No. 10,709,660

METHOD OF PROVIDING BIRTH CONTROL

The Population Council, I...

1. A method of providing birth control, the method comprising:(a) initially inserting into the vagina of a female of reproductive potential on either day 2, 3, 4, or 5 of the female's menstrual cycle, a vaginal system comprising:
a silicone elastomer ring body, a first channel within the ring body, a second channel within the ring body, a first core disposed within the first channel, a second core disposed within the second channel, 103 mg of segesterone acetate, and 17.4 mg ethinyl estradiol, wherein the 103 mg of segesterone acetate is distributed throughout the first core and the second core; wherein the second core contains the 17.4 mg of ethinyl estradiol; wherein the first core is approximately 3.0 mm in diameter and approximately 11 mm in length and releases segesterone acetate alone; wherein the second core is approximately 3.0 mm and approximately 18 mm in length and releases both segesterone acetate and ethinyl estradiol;
wherein the system releases an average of approximately 0.15 mg/day of segesterone acetate and an average of approximately 0.013 mg/day of ethinyl estradiol each day in a 21-day first period as measured across thirteen 28-day product-use cycles; and
wherein the initial insertion on day 2, 3, 4, or 5 is the first day of the 21-day first period;
(b) removing the vaginal system on the day following the end of the 21-day first period;
(c) storing the removed vaginal system for a second period of between five and seven days including the removal date of step (b), wherein the 21-day first period and second period together comprise a product-use cycle; and
(d) repeating steps (a), (b), and (c) for a total of up to thirteen product-use cycles including a first product-use cycle, wherein each initial insertion of step (a) is performed at approximately the same time of day as in a previous product-use cycle.
US Pat. No. 10,709,661

ORAL PARTICULATE COMPOSITION

1. A free-flowing particulate composition suitable for oral consumption, comprising:a carrier phase which is a free-flowing particulate phase comprising (a) a bitter tasting agent having a mean particle size, inclusive of any encapsulant, coating or other substrate, of less than 500 ?m, and (b) a first particulate agent which is sugar particles having a mean particle size of 100-500 ?m; and
a retained phase which is a free-flowing particulate phase, comprising a second particulate agent, wherein the second particulate agent comprises particles comprising a sugar having a mean particle size of at least 800 ?m, and wherein the second particulate agent is other than chewing gum; and
wherein the particles of the retained phase are able to move freely with respect to the particles of the carrier phase, the size of particles of the second particulate agent are larger than those of the first particulate agent, and D75 of the second particulate agent is greater than D75 of the first particulate agent.
US Pat. No. 10,709,149

PREPARATION OF COFFEE FRUIT EXTRACTS AND POWDERS

KoffeeFruit Pte. Ltd., S...

1. A method for preparing a coffee fruit extract having antioxidant activity, the method comprising:(a) providing de-beaned coffee cherries;
(b) freezing the de-beaned coffee cherries under substantially oxygen-free conditions at a temperature of less than about ?30° Fahrenheit (F) to produce frozen de-beaned coffee cherries;
(c) thawing the frozen de-beaned coffee cherries to produce thawed de-beaned coffee cherries; and
(d) extracting antioxidants from the thawed de-beaned coffee cherries in a heated aqueous solvent to produce a coffee fruit extract having antioxidant activity and extracted de-beaned coffee cherries.
US Pat. No. 10,711,456

FIRE-PROOF THERMAL-INSULATION BOARD OF B02 AUTOCLAVED AERATED LIGHTWEIGHT CONCRETE AND METHOD FOR PREPARING SAME

1. A fire-proof thermal-insulation board of B02 autoclaved aerated lightweight concrete, characterized in that components of the fire-proof thermal-insulation board of the B02 autoclaved aerated lightweight concrete are quartz sand, lime, cement, gypsum, aluminum powder, and foam stabilizer; wherein weight percentages of the components are: 56%˜60% of the quartz sand, 8%˜11% of the lime, 20%˜30% of the cement, 2%˜4% of the gypsum, 0.24%˜0.26% of the aluminum powder, and 0.02%˜0.03% of the foam stabilizer.
US Pat. No. 10,714,788

SILICATE COMPOUNDS AS SOLID LI-ION CONDUCTORS

UNIVERSITY OF MARYLAND, C...

1. A solid state lithium battery, comprising:an anode;
a cathode; and
a solid state lithium ion electrolyte located between the anode and the cathode;
wherein
the solid state lithium ion electrolyte comprises a composite material of formula (I):
Liy(M1)x1Si2-x2(M2)x2O7  (I)
wherein
x1 is a number from 0 to 6 inclusive of 0 and 6,
x2 is a number from 0 to 2, inclusive of 0 and 2, and
y is a value such that the composite of formula (I) is charge neutral,
M1 is at least one element selected from the group of elements consisting of a group 1 element, a group 2 element and a group 12 element, and
M2 is at least one element selected from the group of elements consisting of a group 13 element, a group 14 element, and a group 15 element.
US Pat. No. 10,710,945

AROMATIC COMPOSITIONS AND METHODS FOR OBTAINING THEM

ExxonMobil Chemical Paten...

1. A process comprising:(a) obtaining a first aromatic composition from one or more precursor aromatic hydrocarbons, wherein the first aromatic composition comprises one or more of: (i) one or more cycloalkylaromatic compounds; (ii) one or more dicycloalkylaromatic compounds; (iii) one or more biphenyl compounds; and (iv) one or more terphenyl compounds; and
(b) blending the first aromatic composition with a second aromatic composition comprising 8-18 wt % 1-methylnaphthalene, 21-31 wt % 2-methylnaphthalene, 0.1 to 5 wt % 2-ethylnaphthalene, 13-23 wt % dimethyl naphthalene, 2-12 wt % trimethylnaphthalene, 0-15 wt % alkylbenzenes, and 0-15 wt % naphthalene, thereby forming a blended aromatic fluid composition;
wherein obtaining the first aromatic composition comprises one of:
(a-1) contacting a hydroalkylation feed comprising the one or more aromatic hydrocarbons with hydrogen in the presence of a MCM-22 hydroalkylation catalyst so as to produce a hydroalkylation reaction effluent comprising (i) the one or more cycloalkylaromatic compounds and (ii) the one or more dicycloalkylaromatic compounds; and
(a-2) contacting a transalkylation feed comprising the one or more aromatic hydrocarbons with a precursor cycloalkylaromatic compound in the presence of a transalkylation catalyst comprising zeolite beta, zeolite Y, Ultrastable Y (USY), Dealuminated Y (Deal Y), mordenite, ZSM-3, ZSM-4, ZSM-18, ZSM-20, or mixtures thereof, so as to produce a transalkylation reaction effluent comprising the one or more cycloalkylaromatic compounds and the one or more dicycloalkylaromatic compounds.
US Pat. No. 10,711,201

METHOD FOR CONVERTING ALGAL BIOMASS INTO A GAS OR INTO BIOCRUDE BY HYDROTHERMAL GASIFICATION OR HYDROTHERMAL LIQUEFACTION, RESPECTIVELY

1. A method for converting algal biomass into a gas or biocrude with a view to producing a fuel, a motor fuel, or a liquid fuel, or some other synthetic product, comprising:(a) gasification or hydrothermal liquefaction of an algal biomass in at least one first reactor;
(b) separation between respectively the gas or biocrude produced and the aqueous effluents and the CO2 produced at the outlet of the first reactor;
(c) recovery of the aqueous effluents; and
(d) oxidation of the aqueous effluents in at least one second reactor;
wherein step (d) is oxidation by a wet process or a hydrothermal oxidation (HTO) in supercritical conditions.
US Pat. No. 10,709,151

LOW FIBER PENNYCRESS MEAL AND METHODS OF MAKING

COVERCRESS, INC., St. Lo...

1. Pennycress seed meal comprising an acid detergent fiber (ADF) content of 7% to 25% by dry weight, wherein the seed meal is defatted, and wherein said meal comprises a detectable amount of a polynucleotide comprising at least one loss-of-function mutation in an endogenous wild-type pennycress gene comprising the polynucleotide sequence of SEQ ID NO: 71 or at least one loss-of-function mutation in an allelic variant of the endogenous wild-type pennycress gene having at least 95% sequence identity to SEQ ID NO: 71.
US Pat. No. 10,710,946

METHOD OF MANUFACTURING OCTAFLUOROCYCLOPENTENE

ZEON CORPORATION, Chiyod...

1. A method of manufacturing octafluorocyclopentene by bringing 1-choroheptafluorocyclopentene into contact with an alkali metal fluoride to obtain octafluorocyclopentene, comprising:a fluorination step of maintaining, at 85° C. or higher, a suspension containing the alkali metal fluoride suspended in a mixed solvent including a polar aprotic solvent and a glycol ether having a higher boiling point than the polar aprotic solvent while supplying 1-chloroheptafluoropentene into the suspension and performing fluorination thereof to obtain octafluorocyclopentene; and
a recovery step of recovering the octafluorocyclopentene that is produced in the fluorination step.
US Pat. No. 10,709,152

CHLAMYDOMONAS MUTANTS PRODUCED USING RGEN RNP AND METHOD FOR PREPARING PIGMENT USING THE SAME

Industry-University Coope...

1. A Chlamydomonas reinhardtii mutant having a ZEP gene mutation in which a base sequence represented by SEQ ID No. 2 is inserted between a 816th base and a 817th base in a ZEP gene sequence of a Chlamydomonas reinhardtii represented by SEQ ID No. 1 and having an ability to produce a xanthophyll.
US Pat. No. 10,711,204

NITROGEN BASED HYDROGEN SULFIDE SCAVENGERS AND METHOD OF USE THEREOF

Dorf Ketal Chemicals (Ind...

1. A hydrogen sulfide scavenging additive composition for scavenging hydrogen sulfide in hydrocarbon comprising sulfur containing compounds, wherein said additive composition consists of a combination of:(A) at least one nitrogen based hydrogen sulfide scavenger; and
(B) at least one aliphatic tertiary amine,
wherein the nitrogen based hydrogen sulfide scavenger comprises triazine based hydrogen sulfide scavenger; and
wherein the aliphatic tertiary amine comprises tri-isopropanolamine (TIPA), N,N,N?,N?-Tetrakis (2-hydroxyethyl) ethylene-diamine (THEED), ethylene oxide (EO) derivative of TIPA (EO-TIPA), propylene oxide (PO) derivative of TIPA (PO-TIPA), ethylene oxide (EO) derivative of ethylene diamine (EO-EDA), propylene oxide (PO) derivative of ethylene diamine (PO-EDA), or a mixture thereof; and
wherein the composition does not comprise:
a) monoethanol amine (MEA);
b) diethanol amine (DEA); and
c) triethanol amine (TEA).
US Pat. No. 10,709,667

HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS

MASSACHUSETTS INSTITUTE O...

1. A composition comprising:(a) (i) a core comprising a hydrogel forming polymer and optionally encapsulating one or more mammalian secretory, metabolic or structural cells, (ii) an envelope on the outside of the core comprising a hydrogel forming polymer, and (iii) optionally a membrane separating the core and the envelope;
and
(b) one or more anti-inflammatory drugs covalently attached to the hydrogel forming polymer in the envelope by a biodegradable chemical linker;
wherein the one or more anti-inflammatory drugs are locally released from the composition after implantation in a mammalian subject in an amount effective to prevent detectable fibrosis of the composition for at least 10 days.
US Pat. No. 10,710,949

COPPER-CONTAINING MULTIMETALLIC CATALYSTS, AND METHOD FOR USING THE SAME TO MAKE BIOBASED 1,2-PROPANEDIOL

ARCHER DANIELS MIDLAND CO...

1. A process, comprising reacting a glycerol or glycerol-containing feed with hydrogen in the presence of a catalyst comprising copper, zinc and one or more additional metals selected from the group consisting of rhenium, palladium, platinum, ruthenium, manganese, and molybdenum on a zirconia or carbon support to produce a biobased 1,2-propanediol, wherein when a carbon support is used, the carbon has a surface oxygen group concentration corresponding to a desorption of at least 800 ?mol/g combined of carbon monoxide and carbon dioxide through temperature-programmed desorption and analysis with an associated mass spectrometer, and treating the catalyst in the course of reacting the glycerol or glycerol-containing feed with hydrogen by exposure to an alkali metal source.
US Pat. No. 10,711,205

PROCESS FOR RECOVERING HYDROPROCESSED EFFLUENT WITH IMPROVED HYDROGEN RECOVERY

UOP LLC, Des Plaines, IL...

1. A hydroprocessing process comprising:hydroprocessing a hydrocarbon feed stream in a hydroprocessing reactor with a hydrogen stream over hydroprocessing catalyst to provide hydroprocessed effluent stream;
separating said hydroprocessed effluent stream in a hot separator to provide a hot vapor stream and a hot liquid stream;
separating the hot vapor stream in a cold separator to provide a cold vapor stream and a cold liquid stream;
separating the hot liquid stream in a hot flash drum to provide a hot flash vapor stream and a hot flash liquid stream;
separating said cold liquid stream in a cold flash drum to provide a cold flash vapor stream and a cold flash liquid stream; and
mixing said hot flash vapor stream with said cold flash vapor stream to provide a mixed stream.
US Pat. No. 10,710,950

PROCESS FOR THE RECOVERY OF KETONES AND GLYCOLS FROM FERMENTATION

1. A method of obtaining ketones and glycols from a fermentation process, the method comprising:collecting an off-gas and a fermented broth from the fermenter, wherein the off-gas comprises a ketone, and wherein the fermented broth comprises a glycol and a ketone;
performing at least one of: transferring the off-gas from the fermenter to a ketone recuperation module; or transferring the fermented broth to a fluid separating module; and
isolating one or more selected from a group consisting of: the ketone from the off-gas; and
the glycol from the fermented broth.
US Pat. No. 10,709,157

METHODS FOR THE PRODUCTION AND USE OF MYCELIAL LIQUID TISSUE CULTURE

MycoTechnology, Inc., Au...

1. A composition comprising a combination of a food product and a mycelium-free portion from a mycelial liquid tissue culture, wherein the combination comprises a non-nutritive sweetener, wherein the mycelium-free portion is a separated extracellular portion of a liquid tissue culture of Cordyceps sinensis, wherein the combination has reduced bitter tastes compared to the food product alone.
US Pat. No. 10,710,952

PROCESS FOR FLASHING A REACTION MEDIUM

Celanese International Co...

1. A process for producing acetic acid by carbonylating a methanol reactant feed stream in a reactor in the presence of water, rhodium catalyst, iodide salt and methyl iodide to form a reaction medium, the process comprising:separating the reaction medium in a flash vessel into a liquid recycle stream and a vapor product stream comprising acetic acid, from 24 to less than 36 wt. % methyl iodide, from 0.005 to 1 wt. % acetaldehyde, and up to 1 wt. % hydrogen iodide;
distilling at least a portion of the vapor product stream in a first column to obtain a sidedraw comprising acetic acid; and
distilling the acetic acid product stream in a second column to recover a stream near the bottom comprising acetic acid.
US Pat. No. 10,710,953

METHOD FOR PURIFICATION OF GAA

LyondellBasell Acetyls, L...

1. A method comprising:contacting methanol with carbon monoxide in the presence of a liquid reaction medium under carbonylation conditions to form a carbonylation product comprising acetic acid;
separating the carbonylation product into a liquid fraction and a vapor fraction comprising a majority of the acetic acid in the carbonylation product;
removing, from the vapor fraction, water, light ends having a boiling point less than that of acetic acid, heavy ends having a boiling point greater than that of acetic acid, or a combination thereof, to yield a crude acetic acid product comprising at least 99.5 weight percent (wt %) acetic acid, less than or equal to 0.2 wt % water, and less than or equal to 2000 ppm oxidizable impurities, based on the total weight of the crude acetic acid product; and
contacting the crude acetic acid product with an acidic ion exchange resin to provide a purified acetic acid product comprising less than 100 ppm oxidizable impurities.
US Pat. No. 10,709,159

INCREASING THE BIOAVAILABILITY OF FLAVAN-3-OLS WITH CARBOHYDRATES WITH A LOW GLYCEMIC INDEX

Societe des Produits Nest...

1. A non-therapeutic method of increasing the bioavailability of at least one flavan-3-ol to reduce a visible or tangible imperfection of skin of an individual having the visible or tangible imperfection, the method comprising administering a composition to the individual having the visible or tangible imperfection, the composition comprising the at least one flavan-3-ol and a carbohydrate consisting of galactose, wherein the composition comprises the carbohydrate and the at least one flavan-3-ol in a weight ratio of 1:1 to 1:3, wherein the at least one flavan-3-ol is selected from the group consisting of (+)-catechin (C), (?)-epicatechin (EC), gallocatechin (GC), gallocatechin gallate (GCG), (?)-epigallocatechin (EGC), (?)-epigallocatechin-3-gallate (EGCg), (?)-epicatechin-3-gallate (ECg), and mixtures thereof.
US Pat. No. 10,709,160

SOLUBLE CALCIUM STABILISED IN AN ANIONIC-CATIONIC POLYMER AND FRUCTANS

Centro de Investigacion y...

1. A method for a preparation of a stabilized soluble calcium complex including a) a source of calcium present in an amount of 0.05 mg to 15 mg per gram of a sample, b) a cationic polymer present in a mass ratio to the calcium source of between 0.25 and 12.5, c) an anionic hydrocolloid, and d) a source of a soluble fiber, the method comprising the steps of:a) preparing a first solution containing from 0.05 g to 5 g of a source of calcium, 1 mL of phosphoric acid, and 8 mL of water;
b) preparing a second solution containing from 0.01 g to 4 g of a cationic polymer and 20 mL of 1% glacial acetic acid;
c) producing a third solution by combining the solutions obtained in steps a) and b), maintaining the third solution at a temperature of between 1° C. to 70° C., and maintaining the mass proportions of the source of calcium and cationic polymer between 0.25 and 12.5;
d) maintaining the pH of the solution of subsection c) at a pH of between 1.0 and 6.5, under conditions of rest for 1 to 24 hours, and under a controlled temperature of ?5° C. to 20° C.;
e) dispersing the solution of step d) in an anionic hydrocolloid selected from: arabic gum, guar gum, sodium or potassium alginate, propylene glycol alginate, mesquite gum, xanthan gum, locust bean gum, casein, or pectin;
f) adding a source of soluble fiber selected from: agave fructans, inulin, or a mixture thereof;
g) conditioning the solution of step f) to be supplied in liquid form, reducing the volume of the solution by atomization in a spray dryer to a final concentration of total solids of from 30 g to 35 g per 100 ml of solution.
US Pat. No. 10,709,673

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

GW Research Limited, Cam...

1. An oral composition consisting of: (i) cannabidiol (CBD) at a concentration of between about 22.5 mg/ml and about 110 mg/ml, (ii) ethanol at a concentration of about 71.1 mg/ml to about 86.9 mg/ml, (iii) a sweetener at a concentration of about 0.45 mg/ml to about 0.55 mg/ml, (iv) a flavoring at a concentration of about 0.18 mg/ml to about 0.22 mg/ml, and (v) sesame oil q.s. to about 1.0 ml.
US Pat. No. 10,710,955

METHODS FOR PRODUCING ALKYL HYDROXYALKANOATES

CARGILL, INCORPORATED, W...

1. A method for producing an alkyl 3-hydroxypropionate, comprising:a) obtaining a 3-hydroxypropionate containing composition derived from a 3-hydroxypropionic acid recovery bottom stream, the composition, comprising:
(i) at least 40 percent by weight 3-hydroxypropionate equivalents;
(ii) greater than 0 and less than 45 percent by weight free 3-hydroxypropionate;
(iii) at least 1 percent by weight saccharide equivalents; and
(iv) less than 15 percent by weight water;
b) mixing a mono-alcohol in a molar ratio of from about 1.1:1.0 to 10.0:1.0 of mono-alcohol to 3-hydroxypropionate equivalents present in the 3-hydroxypropionate containing composition to obtain a first mixture;
c) heating the first mixture to form a reaction product;
d) distilling the reaction product and recovering an alkyl 3-hydroxypropionate fraction comprising:
(i) at least 90 percent by weight alkyl 3-hydroxypropionate;
(ii) less than 1 percent by weight 3-hydroxypropionate acid;
(iii) less than 1 percent by weight water; and
(iv) less than 0.5 percent by weight saccharide equivalents.
US Pat. No. 10,709,674

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

GW Research Limited, Cam...

1. A method of treating seizures in a patient with Lennox-Gastaut syndrome or Dravet syndrome, comprising orally administering to the patient in need thereof cannabidiol (CBD), wherein:(a) the CBD has a purity of at least 95% (w/w); and
(b) the CBD is administered in a composition, consisting of:
(i) CBD at a concentration ranging from about 22.5 mg/mL and about 110 mg/mL;
(ii) ethanol at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL;
(iii) a sweetener at a concentration ranging about 0.45 mg/mL to about 0.55 mg/mL;
(iv) flavoring at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL;
and (v) a solvent q.s. to about 1.0 ml.
US Pat. No. 10,709,675

NUTRACEUTICAL COMPOSITIONS COMPRISING C60 AND CURCUMIN

1. A nutraceutical composition comprising a fullerene, curcumin, and at least one of black seed oil and moringa oil, wherein the composition is substantially free of particles having a size of greater than 0.2 ?m.
US Pat. No. 10,709,676

APPLICATIONS OF SPERMINE AND DERIVATIVES THEREOF

Geneheal Biotechnology Co...

1. A method for treating or alleviating a disease comprising:administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or C1-C6 amide thereof to a patient in need thereof,
wherein the compound is spermine and the disease is ADSL deficiency.
US Pat. No. 10,709,164

REDUCED RISK TOBACCO PRODUCTS AND METHODS OF MAKING SAME

Vector Tobacco Inc., Mor...

1. A method of producing a transgenic tobacco plant comprising inhibiting expression of an endogenous gene comprising SEQ. ID. NO: 5 by RNA interference (RNAi) in a tobacco plant, wherein leaves from said transgenic tobacco plant have a reduced amount of nornicotine or nicotine or both nornicotine and nicotine, as compared to a control tobacco.
US Pat. No. 10,709,165

VAPORIZABLE TOBACCO WAX COMPOSITIONS

BOND STREET MANUFACTURING...

1. A vaporizable tobacco wax composition comprising tobacco wax and a vapor agent, wherein the vaporizable tobacco wax composition has a wax consistency, the vapor agent is present in the amount of 10-25% by mass, the composition has a nicotine content of 1.5-4%, the tobacco wax is extracted from tobacco using supercritical CO2 extraction, and the composition has a TSNA content of less than 1 ppm.
US Pat. No. 10,709,679

ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS

ARSTAT, INC., Flemington...

1. A method for relieving menstrual pain and reducing menstrual blood loss in a female comprising:administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 150 mg to 200 mg per the oral combination drug formulation; wherein a total daily dose of the tranexamic acid ranges from 390 mg to 500 mg.
US Pat. No. 10,711,217

LUBRICANT BASE OIL

NOF CORPORATION, Tokyo (...

1. A lubricant base oil consisting of an ester, said ester comprising:a component (A) derived from pentaerythritol in a molar percentage Amol % of 20 to 30 mol %;
a component (B) derived from a straight-chain fatty acid having a carbon number of 14 to 22 in a molar percentage Bmol % of 55 to 79 mol %; and
a component (C) derived from adipic acid in a molar percentage Cmol % of 1 to 15 mol %,
wherein a molar ratio (Cmol/Bmol) of said component (C) derived from adipic acid and said component (B) derived from said straight-chain fatty acid having a carbon number of 14 to 22 is 0.02 to 0.25, and
wherein said ester has a hydroxyl value of 10 to 100 mgKOH/g.
US Pat. No. 10,709,680

METHODS FOR TREATING DRY EYE

1. A method for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of:administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to said mammal having inflamed or dysfunctional meibomian glands, wherein said amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form; and wherein said composition is devoid of omega-6 fatty acids;
increasing levels of anti-inflammatory omega-3's in the meibum composition of said treated meibomian glands of said mammal; and
decreasing levels of inflammatory omega-6's in the meibum composition of said treated meibomian glands.
US Pat. No. 10,709,684

SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE

Pfizer Inc., New York, N...

1. A method of lowering urinary albumin excretion in a patient comprising administering ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof to the patient, wherein the patient has moderate renal impairment or stage 3 chronic kidney disease (CKD).
US Pat. No. 10,709,685

USE OF METHADONE METABOLITES FOR TREATMENT OF ANXIETY AND DEPRESSION

Georgetown University, W...

1. A method of treating anxiety, comprising administering to a subject in need thereof a therapeutically effective amount of 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP), or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,711,223

COMPOSITION COMPRISING POLYALKYLENEIMINES

RECKITT BENCKISER FINISH ...

1. A composition comprising a polyalkyleneimine, a salt of a polyalkyleneimine, and/or a derivative of a polyalkyleneimine in an amount of 0.01 mg to 10 mg per wash and/or rinse cycle of an automatic dishwashing machine,wherein the composition is provided to the automatic dishwashing machine.
US Pat. No. 10,711,224

COMPOSITIONS AND METHODS USEFUL FOR REMOVING TABLET COATINGS

Ecolab USA Inc., St. Pau...

1. A method for removing an acrylic-based polymeric material from a pharmaceutical equipment surface comprising:(a) diluting a concentrate composition with water to form a diluted composition, the concentrate composition comprising:
about 50 wt.-% to about 90 wt.-% diethylene glycol monobutyl ether;
about 0.5 wt.-% to about 3 wt.-% of at least one C2 to C10 organic acid; and
water,
(b) contacting the pharmaceutical equipment surface with the diluted composition for 30 seconds to 2 hours at a temperature of about 23° C. to about 80° C. as part of a clean-in-place process, the diluted composition having a pH from about 4.5 to about 6.0
and
(c) removing the acrylic-based polymeric material with the diluted composition from the pharmaceutical equipment surface.
US Pat. No. 10,709,687

FLT3 RECEPTOR INHIBITOR AT LOW DOSAGE FOR THE TREATMENT OF NEUROPATHIC PAIN

UNIVERSITE DE MONTPELLIER...

1. A method for the treatment of neuropathic pain and chronic pain in which neuropathic pain coexists with a type of pain different from neuropathic pain, the method comprising the step of administering to a patient in need thereof a FLT3 receptor inhibitor, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of:(i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity in a model of nerve injury, which is the Spinal Nerve Ligation Model in rats,
(ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, the daily dose being calculated as the daily dose for a human with a body weight of 60 kg, and
(iii) establishing a daily dosage range per human adult per day wherein the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg and the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.
US Pat. No. 10,711,225

COMPACTED LIQUID LAUNDRY DETERGENT COMPOSITION

1. A water-soluble unit dose article comprising a water-soluble film and a liquid laundry detergent composition comprising:a. a liquid phase;
b. a lamellar liquid crystal phase comprising an anionic surfactant selected from a non-amine neutralized linear alkylbenzene sulphonate, a non-amine neutralized alkyl sulphate, or a mixture thereof;
c. a particulate phase;wherein the lamellar liquid phase and particulate phase are dispersed within the liquid phase and wherein the particulate phase is defined as the solid obtained when the liquid laundry detergent composition is centrifuged at about 1200 G for about 10 mins and wherein the term ‘lamellar liquid crystal’ means the system being in a state where the surfactant molecules are organised in stacks of bilayers of surfactant in the melted state separated by thin layers of solvent; andwherein the liquid phase comprises between about 5% and about 40% by weight of the liquid of an alcohol selected from the group consisting of ethylene glycol, 1,3 propanediol, 1,2 propanediol, tetramethylene glycol, pentamethylene glycol, hexamethylene glycol, 2,3-butane diol, 1,3 butanediol, diethylene glycol, triethylene glycol, polyethylene glycol, glycerol formal, dipropylene glycol, polypropylene glycol, dipropylene glycol n-butyl ether, and mixtures thereof; andwherein the composition has an equilibrium relative humidity of less than about 65% at about 20° C. as measured via the composition eRH test described herein; andwherein the composition comprises less than about 5% by weight of the composition of a hydroxyl-containing amine compound,wherein the composition comprises between about 5% and about 35%, by weight of the composition of the lamellar liquid crystal phase,wherein the composition comprises between about 25% and about 55% by weight of the composition of the particulate phase,wherein the composition comprises less than 2% by weight of the composition of a structurant, wherein the structurant is a cellulose-fibre based structurants, and wherein the composition comprises between about 0.5% and about 15% by weight of the composition of water;wherein the liquid laundry detergent composition exhibits a viscosity of less than 1560 mPa·s at 0.05s-1 and less than 870 mPa·s at 1000s-1.
US Pat. No. 10,711,226

COMPOSITION FOR CLEANING SKIN STRIPS OF SKIN SKIS

VAUHTI SPEED OY, Joensuu...

1. A method for cleaning skin strips of skin skis comprising contacting a surface of a skin strip with a composition comprising(a) C1-6-alcohol;
(b) at least 10% by weight of the total weight of the composition of dibasic ester of formula (I)
R1O—C(O)—(CH2)n—C(O)—OR1  (I)
wherein
n is 2-4; and
each R1 is independently C1-6-alkyl;
(c) 0 to 5% by weight of the total weight of the composition of alkoxyalkanol of formula (II)
R2O—(CH2)m—OH  (II)
wherein
m is 1 to 4, and
R2 is C1-6-alkyl; and
(d) 0 to 5% by weight of the total weight of the composition of tri(C1-6-alkanol)amine.
US Pat. No. 10,709,689

PHARMACEUTICAL COMPOSITION

SLA PHARMA AG, Liestal (...

1. A topical composition consisting of metronidazole and a pharmacologically acceptable non-aqueous vehicle selected from the group consisting of petrolatum and lanolin, wherein the metronidazole is present in a concentration of about 5 wt % to about 15 wt %, based on the total weight of the composition, and wherein the topical composition has a fluffy texture for direct application to the colon, rectum, anorectum, perianal region or anal canal.
US Pat. No. 10,709,690

COMBINATION THERAPY WITH NITRATED LIPIDS AND INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

THE UNIVERSITY OF UTAH RE...

1. A method comprising administering 10-nitrooleic acid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat chronic kidney disease or diabetic nephropathy.
US Pat. No. 10,711,230

N-ACYL PROLINE DERIVATIVES AS FOOD FLAVORING COMPOUNDS

Givaudan SA, Vernier (CH...

1. A flavour composition comprising a compound selected from the group consisting of:N-geranoyl-Pro,
N-palmiteneoyl-Pro,
N-stearoyl-Pro,
N-oleoyl-Pro,
N-linoleoyl-Pro, and,
N-linolenoyl-Pro, wherein,
the compound accentuates the existing flavour or existing mouth feel characteristics of edible foodstuff products further comprising at least one flavour co-ingredient, or of beverage products further comprising at least one flavour co-ingredient, when the said compound is incorporated in an amount of 1 ppb-10 ppm within the edible foodstuff product or beverage product.
US Pat. No. 10,712,254

METHOD OF ANALYZING POST-TRANSLATIONAL MODIFICATIONS

OXFORD UNIVERSITY INNOVAT...

1. A method for determining the number or position(s) of one or more post-translational modifications (PTMs) in a peptide, polypeptide or protein, the method comprising:(a) contacting the peptide, polypeptide or protein with a transmembrane pore such that the peptide, polypeptide or protein moves through the pore; and
(b) taking one or more current measurements as the peptide, polypeptide or protein moves with respect to the pore and thereby determining the number or position(s) of one or more PTMs in the peptide, polypeptide or protein;
wherein the peptide, polypeptide or protein is attached to an oligonucleotide.
US Pat. No. 10,711,232

BIOREACTOR FOR MICROALGAE

Inria Institut National D...

1. A bioreactor comprising a light source and a tank comprising a culture medium in which a cell culture consisting of green algal cells is dispersed, said green algal cell culture having a concentration of greater than 0.1 g/l in the culture medium, each green algal cell having a minimum absorption for light in a range of wavelengths between 500 nm and 600 nm, said light source being configured to emit incident light in the direction of the tank consisting of at least 60% of photons having a wavelength between 500 nm and 600 nm.
US Pat. No. 10,711,235

GAS PERMEABLE MATERIAL

Saint-Gobain Performance ...

1. An oxygen permeable film comprising:a first polymer layer having a thickness in the range of about 0.01 mm to about 5 mm; and
a second fluid contact layer having a total organic carbon (TOC) in water of less than 1 mg/cm2, the second fluid contact layer having a thickness in the range of about 0.01 mm to about 0.1 mm,
wherein the first polymer layer and the second fluid contact layer are adhered together, and
wherein the oxygen permeable film has an oxygen permeability of at least 2000 cc/m2 per day.
US Pat. No. 10,709,700

ARIMOCLOMOL FORMULATION

1. A method of reducing inhibition of OCT2 in an individual in need of reduced inhibition of OCT2 and in need of treatment with an agent selected from the group consisting of: N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, a stereoisomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an acid addition salt of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and an addition salt of a stereoisomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; comprising:administering an effective amount of an extended-release pharmaceutical formulation in an oral dosage form comprising:
an active pharmaceutical ingredient selected from the group consisting of: N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, a stereoisomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, an acid addition salt of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride and an addition salt of a stereoisomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; and
a release-controlling excipient that provides for extended release of said active pharmaceutical ingredient reducing inhibition of OCT2 as compared to an immediate-release formulation of an equivalent amount of the active pharmaceutical ingredient;
wherein the extended-release pharmaceutical formulation provides for a Cmax of the active pharmaceutical ingredient of less than 15 ?M, and wherein the agent is present in one dosage form or formulation unit in a total amount of 5-1000 mg per dosage, thereby reducing inhibition of OCT2 in the individual.
US Pat. No. 10,709,701

EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (HL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS

Immunomedics, Inc., Morr...

1. A method of treating an HLA-DR+ cancer comprising administering to a human patient with an HLA-DR+ cancer an immunoconjugate IMMU-140.
US Pat. No. 10,710,982

(S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS

1. A process for preparing a composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate,wherein said process comprises the steps of:
a) blending (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide hydrate form 2 and hypromellose acetate succinate to form a blend,
b) extruding the blend through a twin screw hot melt extruder to form an extrudate,
c) quenching the extrudate on an air cooled conveyor belt or using a chilled roller to form quenched extrudate comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide amorphous form, and
d) pelletizing the extrudate to form pellets and subsequently milling the pellets to form a ground product.
US Pat. No. 10,709,702

TREATMENT OF SKIN DISORDERS BY TOPICAL ADMINISTRATION OF VEGF INHIBITORS

AMD THERAPEUTICS LLC, Pa...

1. A method of reducing or preventing skin redness, eczema, or dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of a formulation consisting essentially of from 1 to 5% of a rifamycin compound as the sole active ingredient in the formulation.
US Pat. No. 10,709,704

TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS

Georgetown University, W...

1. A method of treating a neurodegenerative disease in a subject in need thereof, comprising:selecting a subject with a neurodegenerative disease of the central nervous system or at risk for a neurodegenerative disease of the central nervous system; and
systemically administering to the subject an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor crosses the blood brain barrier, wherein the effective amount of the tyrosine kinase inhibitor is less than 10 mg/kg, and wherein the effective amount of the tyrosine kinase inhibitor is lower than a chemotherapeutic dosage, wherein the tyrosine kinase inhibitor is selected from the group consisting of nilotinib, bosutinib, and a combination thereof.
US Pat. No. 10,711,243

MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT

MEMORIAL SLOAN-KETTERING ...

1. An in vitro method for differentiating pluripotent stem cells, comprising: exposing a plurality of pluripotent stem cells to at least one inhibitor of transforming growth factor beta (TGF?)/Activin-Nodal signaling and at least one inhibitor of bone morphogenetic protein (BMP) signaling, and exposing the cells to at least one activator of Sonic hedgehog (SHH) signaling and at least one glycogen synthesis kinase 3? (GSK3?) inhibitor that activates wingless (Wnt) signaling, wherein the cells are exposed to the at least one GSK3? inhibitor three (3) days from the initial exposure of the cells to the at least one inhibitor of TGF?/Activin-Nodal signaling and the at least one inhibitor of BMP signaling to obtain a cell population comprising greater than about 40% differentiated cells expressing both forkhead box protein A2 (FOXA2) and LIM homeobox transcription factor 1 alpha (LMX1A), and wherein the at least one activator of SHH signaling is selected from the group consisting of a Smoothened agonist (SAG), a modified N-terminal SHH, and a SHH protein comprising a N-terminal fragment and a C-terminal fragment.
US Pat. No. 10,709,707

METHODS OF TREATING OCULAR CONDITIONS

Oyster Point Pharma, Inc....

1. A method of treating dry eye, comprising the local administration of a therapeutically effective amount of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, or a pharmaceutically acceptable salt thereof, in alternating nostrils of an individual in need thereof.
US Pat. No. 10,710,989

METHOD FOR PRODUCING HETEROCYCLIC COMPOUND

TAKEDA PHARMACEUTICAL COM...

1. A method of producing 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-5-methyl-1-oxo-6-(4-(1H-pyrazol-1-yl)benzyl)-1,3-dihydro-2H-isoindol-2-yl)-L-threo-pentitol or a salt thereof, which comprises reacting 4-fluoro-3-hydroxy-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2-benzofuran-1(3H)-one or a salt thereof, 3-fluoro-2-formyl-4-methyl-5-[4-(1H-pyrazol-1-yl)benzyl]benzoic acid or a salt thereof, or a mixture thereof with 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol.
US Pat. No. 10,711,245

DIRECT CONVERSION METHOD OF HUMAN FIBROBLASTS INTO NEURAL STEM CELLS USING SMALL MOLECULES

INSTEMCARE INC., Seoul (...

1. A method for producing neural stem cells, the method comprising:culturing human fibroblasts in a medium comprising Thiazovivin, Valproic acid, Purmorphamine, A8301, SB431542, CHIR99021, DZNep(Deazaneplanocin A), and 5-AZA.
US Pat. No. 10,711,248

DEVICE AND METHOD FOR STANDARDIZING MYOBLAST DIFFERENTIATION INTO MYOTUBES

CYTOO, Grenoble (FR)

1. A device for controlling myoblast differentiation into myotubes with standardized morphological parameters, comprising a substrate and at least one cell-adhesive pattern for culturing myoblasts on said substrate, wherein:said pattern has an elongated surface comprising a central region and two lateral regions extending from said central region in both directions along a longitudinal axis of the pattern with a contour discontinuity between the central region and each lateral region, a length of the pattern being between 100 and 1000 ?m and a maximum width of said pattern being between 50 and 500 ?m,
a ratio between a maximum width of the central region and a maximum width of the lateral regions is greater than or equal to 2,
a ratio between the length and the maximum width of the pattern is less than or equal to and
wherein the pattern consists of three elliptical surfaces partially superimposed in the central region of the pattern:
a first elliptical surface defining the central region of the pattern; and
second and third elliptical surfaces having a major axis coinciding with a major axis of the first ellipse defining the lateral regions of the pattern,
wherein the second and third elliptical surfaces intersect the first elliptical surface along their transversal axis.
US Pat. No. 10,711,249

METHOD FOR INDUCING HEPATOCYTES

KYOTO UNIVERSITY, Kyoto ...

1. A method for producing hepatocytes from pluripotent stem cells, comprising the following steps (i) to (iii):(i) culturing pluripotent stem cells in a medium containing Activin A and a GSK-3? inhibitor,
(ii) culturing the cells obtained in step (i) in a medium containing DMSO, and
(iii) culturing the cells obtained in step (ii) in a medium for culturing hepatocytes containing pregnenolone; wherein said step produces hepatocytes.
US Pat. No. 10,711,250

EX VIVO PROLIFERATION OF EPITHELIAL CELLS

PROPAGENIX INC., Rockvil...

18. A method for proliferating epithelial cells ex vivo, comprising:expanding the number of cells in an originating epithelial cell population derived from induced pluripotent stem cells (iPSCs) under serum-free and feeder-cell free expansion culture conditions, thereby generating an expanded epithelial cell population, wherein the expansion culture conditions comprise
a) one or more transforming growth factor beta (TGF-beta) inhibitors;
b) one or more agents that modulate cytoskeletal structure;
c) a beta-adrenergic receptor agonist;
d) one or more mitogenic growth factors; and
e) calcium at a concentration below 100 ?M.
US Pat. No. 10,709,714

GASTRIN ANTAGONISTS FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS

Clifton Life Sciences LLC...

1. A method for treating osteoporosis in a human subject in need thereof, comprising administering to the human subject at least one dose of a therapeutically effective amount of YF476, thereby treating the osteoporosis.
US Pat. No. 10,711,251

EX VIVO PROLIFERATION OF EPITHELIAL CELLS

PROPAGENIX INC., Rockvil...

22. A composition comprisinga) a cell population comprising one or more of basal epithelial cells, epithelial progenitor cells, epithelial precursor cells, differentiating epithelial cells, differentiated epithelial cells, and transit-amplifying epithelial cells;
b) one or more transforming growth factor beta (TGF-beta) inhibitors; and
c) one or more agents that modulate cytoskeletal structure.
US Pat. No. 10,711,253

COMPOSITIONS OF AND METHODS FOR IN VITRO VIRAL GENOME ENGINEERING

1. A recombinant phage that expresses two or more payloads selected from the group consisting of a DNase, an exopolysaccharide (EPS) depolymerase, and one or more surfactant phenol soluble modulins.
US Pat. No. 10,709,724

METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION

Ecole Polytechnique Feder...

1. A method of treating a disorder associated with mitochondrial dysfunction, the method comprising administering to a subject in need thereof:(a) a poly(ADP-ribose) polymerase (PARP) inhibitor; and
(b) one or more compounds that increases intracellular and mitochondrial nicotinamide adenine dinucleotide (NAD+) in an amount sufficient to induce Sirtuin 1 (SIRT1) or Sirtuin 3 (SIRT3) protein expression,
wherein the PARP inhibitor is N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride (PJ34), Thieno[2,3-c]isoquinolin-5-one (TIQ), 4-iodo-3-nitrobenzamide (Iniparib or BSI-201), 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one (Olaparib or AXD2281), 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (Veliparib or ABT-888), 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one (Rucaparib or AG014699), 11-methoxy-2-((4-methylpiperazin-1-yl)methyl)-4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione (CEP-9722), or 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide (Niraparib or MK 4827), and wherein said disorder associated with mitochondrial dysfunction is a neurodegenerative disease.
US Pat. No. 10,711,272

CTLA-4 APTAMER SIRNA SPECIES

City of Hope, Duarte, CA...

1. A nucleic acid compound comprising a monomeric CTLA-4 aptamer nucleic acid conjugated to a cell activity modulating nucleic acid, wherein the nucleic acid is an anti-cancer siRNA.
US Pat. No. 10,709,738

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 47,wherein said cancer is selected from colorectal cancer (CRC), gallbladder cancer (GBC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), and renal cell carcinoma (RCC).
US Pat. No. 10,711,276

SEQUENCE VARIANTS

Sandoz AG, Basel (CH)

1. A method for optimizing the coding sequence of a polynucleotide that encodes a polypeptide, the method comprising(a) changing at least one codon within said coding sequence to an alternative codon, wherein said at least one codon is susceptible to amino acid residue misincorporation at a position within the encoded polypeptide that corresponds to said codon so as to change the degree or type of amino acid residue misincorporation; or
(b) identification of at least one codon within said coding sequence which is susceptible to amino acid residue misincorporation at a position within the encoded polypeptide that corresponds to said codon and changing said codon to an alternative codon so as to change the degree or type of amino acid residue misincorporation
wherein the polypeptide is recombinantly expressed from the polynucleotide coding sequence incorporating the alternative codon, by transcription and/or translation of the coding sequence in a host cell; and wherein said method comprises determining the degree or type of amino acid residue
misincorporation found in:
a) the polypeptide obtained by expression of said polynucleotide to be optimized; and/or
b) a polypeptide obtainable by expression of a second polynucleotide which encodes the same polypeptide but differs in said at least one codon from the polynucleotide to be optimized;
wherein determining the degree or type of amino acid residue misincorporation comprises the use of mass spectrometry (MS), and
wherein a codon susceptible to amino acid residue misincorporation is a codon that, if altered by at least one base difference due to non-Watson-Crick base mismatches during transcription or translation, would encode another amino acid residue.
US Pat. No. 10,709,741

COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE

NATIONAL UNIVERSITY CORPO...

1. A method of treating an inflammatory disease comprising, administering to a subject in need thereof an effective amount of a composition comprising a culture supernatant, wherein the culture supernatant is obtained by a method comprising(1) selecting adherent cells from dental pulp cells, and
(2) culturing the adherent cells to at least 70% confluence,
(3) culturing the cells obtained in step (2) in serum-free liquid, and
(4) obtaining the supernatant,wherein the composition does not contain dental pulp stem cells, andwherein the inflammatory disease is selected from the group consisting of fulminant hepatitis, hepatic cirrhosis, pulmonary fibrosis, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
US Pat. No. 10,711,279

PROMOTER SEQUENCES

SANDOZ AG, Basel (CH)

1. An expression cassette comprising:a polynucleotide that is:
(i) a fragment of SEQ ID NO: 1, wherein the fragment comprises nt 579 to nt 800 of the sequence as set forth in SEQ ID NO:1;
(ii) a nucleic acid sequence having at least 90% identity to (i);
(iii) the nucleic acid sequence as set forth in SEQ ID NO: 1;
(iv) a nucleic acid sequence having at least 75% identity to (iii); or
(v) the complementary sequence of (i), (ii), (iii) or (iv);anda heterologous coding sequence.
US Pat. No. 10,709,745

TROPIC CELL BASED VIROTHERAPY FOR THE TREATMENT OF CANCER

CITY OF HOPE, Duarte, CA...

1. A pharmaceutical composition for treating cancer, comprising a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule, and wherein the tropic cell is a stem cell from a neural stem cell line HB1.F3-CD.
US Pat. No. 10,711,287

D-LACTATE DEHYDROGENASE, ENGINEERED STRAIN CONTAINING D-LACTATE DEHYDROGENASE AND CONSTRUCTION METHOD AND USE OF ENGINEERED STRAIN

Shanghai Jiao Tong Univer...

1. A D-lactate dehydrogenase comprising a substitution, deletion, insertion, addition of one or more amino acid residues, wherein said D-lactate dehydrogenase comprises an amino acid sequence having at least 80% and less than 100% sequence identity to SEQ ID NO: 1, and wherein said D-lactate dehydrogenase has D-lactate dehydrogenase activity.
US Pat. No. 10,711,288

METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES

GENOMATICA, INC., San Di...

1. A recombinant microorganism engineered to express a CYP153A-reductase hybrid fusion polypeptide variant comprising a CYP153A ?-hydroxylase domain and a P450RhF reductase domain; wherein the hybrid fusion polypeptide variant has at least 91% sequence identity to SEQ ID NO: 6 and has one or more mutations selected from the group consisting of V141I, V141T, V141Q, V141G, V141M, V141L, R27L, R82D, R178N, A231T, N309R, N407A, V415R, T516V, P666A, P666D and A796V.
US Pat. No. 10,711,289

METHOD OF PRODUCING AND PROCESSING DIAMINES FROM AN ENGINEERED MICROORGANISM

GENOMATICA, INC., San Di...

1. A process for diamine (DA) production comprising the steps of:a) culturing a genetically engineered microorganism comprising a diamine (DA) synthesis pathway selected from the group consisting of hexamethylenediamine, cadaverine, putrescine, ethylenediamine and heptamethylenediamine with at least one exogenous nucleic acid encoding at least one enzyme of the DA synthesis pathway for producing a DA in medium under suitable conditions and for a sufficient period of time to produce DA and form one or more of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate in a cultured medium and a carbonic anhydrase in sufficient amount to (a) enhance the formation of the DA carbonate, DA bicarbonate, and/or, DA bis-bicarbonate by converting carbon dioxide to a bicarbonate and/or carbonate ions, (b) enhance the release of carbon dioxide from a solution of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate by converting a bicarbonate and/or carbonate ions to carbon dioxide, or (c) both (a) and (b);
wherein
i) carbon dioxide, carbonate, bicarbonate or carbonic acid predominantly control pH of the medium;
ii) percent dissolved inorganic carbon (DIC) in the medium is greater than or equal to 40%; and the DIC is determined by the formula:
DIC/TDCA×100
where TDCA is the Total Dissolved Counter Anions and is the sum of DIC and other anions; or
iii) at least 40% of diamine species in the medium comprises one or more of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate;
b) converting at least one or more of the DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate into DA free base and carbon dioxide; and
c) isolating the DA free base.
US Pat. No. 10,711,295

COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF SALMONELLA

Gen-Probe Incorporated, ...

16. A method for detecting Salmonella in a sample, said method comprising a detecting step of detecting the presence or absence of a Salmonella target nucleic acid using the detection oligonucleotide of claim 1.
US Pat. No. 10,709,760

TREATMENT OF CHRONIC ULCERS

Promore Pharma AB, Solna...

1. A method of treating a chronic ulcer, wherein said method comprises:(a) topically applying to said chronic ulcer a pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution comprising LL-37 or a pharmaceutically-acceptable salt thereof, wherein the pharmaceutical formulation comprises one thickening agent; followed by
(b) topically applying a dressing to said chronic ulcer;
wherein the dose of LL-37 applied per cm2 of wound area is between about 1 ?g/cm2 and about 70 ?g/cm2, and wherein the pharmaceutical formulation has a viscosity in the range of about 2 and about 10 Pa·s.
US Pat. No. 10,711,297

AUTOMATED METHOD FOR ANALYZING SAMPLES

Gen-Probe Incorporated, ...

1. An automated method for analyzing a plurality of samples, the method comprising performing within a housing of a self-contained system the steps of:(a) loading the system with the plurality of samples;
(b) after step (a), performing a first assay on a first sample subset of the plurality of samples, the first assay comprising:
(i) exposing each sample of a first sample subset to a first target capture reagent comprising a solid support for directly or indirectly immobilizing a first target nucleic acid that may be present in one or more samples of the first sample subset; and
(ii) after step (b)(i), performing in each sample of the first sample subset a first amplification reaction for amplifying a region of the first target nucleic acid; and
(c) after step (a), performing a second assay on a second sample subset of the plurality of samples, the second assay comprising:
(i) exposing each sample of the second sample subset to a second target capture reagent comprising a solid support for directly or indirectly immobilizing a second target nucleic acid that may be present in one or more samples of the second sample subset; and
(ii) after step (c)(i), performing in each sample of the second sample subset a second amplification reaction for amplifying a region of the second target nucleic acid,
wherein for each sample of the first sample subset, step (b)(i) is performed in a first receptacle and step (b)(ii) is performed in a second receptacle, the first and second receptacles having different configurations, and
wherein for each sample of the second sample subset, steps (c)(i) and (c)(ii) are performed in a third receptacle, the first and third receptacles having the same configuration.
US Pat. No. 10,711,043

COMPOSITIONS AND VACCINES COMPRISING VESICLES AND METHODS OF USING THE SAME

University of Maryland, C...

1. A method of generating an antibody response against Neisseria gonorrhoeae in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a catanionic surfactant vesicle;wherein the catanionic surfactant vesicle comprises a unilamellar bilayer comprising a mixture of oppositely charged single-tailed surfactants and one or a plurality of Neisseria gonorrhoeae immunogens from whole Neisseria gonorrhoeae cell extract;
wherein the one or plurality of Neisseria gonorrhoeae immunogens comprise at least one membrane-bound sugar, or at least one membrane-bound polypeptide or at least one combination of a membrane-bound sugar and membrane-bound polypeptide; and wherein the membrane-bound sugar, the membrane-bound polypeptide, or the combination of the membrane-bound sugar and membrane-bound polypeptide is positioned at least partially in the unilamellar bilayer;
wherein the catanionic surfactant vesicle comprises bacterial lipooligosaccharide (LOS) or lipopolysaccharide (LPS) and one or a plurality of Neisseria gonorrhoeae lipoproteins or Neisseria gonorrhoeae membrane-bound protein; and
wherein the catanionic surfactant vesicle comprises a percentage of carbohydrate from about 0% to about 25% by weight.
US Pat. No. 10,711,299

PULSE CALLER AND BASE CALLER

Quantum-Si Incorporated, ...

1. A sequencing instrument, comprising:a photodetector configured to receive light from luminescent labels during nucleotide incorporation events of a sequencing reaction, the luminescent labels being associated with nucleotides; and
a processor configured to:
obtain characteristics of the light, the characteristics including, for individual nucleotide incorporation events,
a temporal characteristic of the light, the temporal characteristic representing a speed of decay of a probability of photon emission by a luminescent label after excitation; and
an intensity characteristic of the light, wherein the temporal characteristic and the intensity characteristic are characteristics of light received from a luminescent label during a nucleotide incorporation event; and
wherein the temporal characteristic and the intensity characteristic are used to perform one or more of: identifying individual nucleotides, and calibrating the sequencing instrument, and
wherein the intensity characteristic represents a quantity of photogenerated charge carriers produced over time by the photodetector from the light received from the luminescent label during the nucleotide incorporation event.
US Pat. No. 10,710,026

ZWITTERIONIC FIBER MEMBRANES

Trustees of Tufts College...

1. A polymer fiber, comprising a plurality of statistical copolymers, wherein each statistical copolymer comprises a plurality of zwitterionic repeat units and a plurality of hydrophobic repeat units, whereinthe zwitterionic repeat units constitute 20-75 wt % of the statistical copolymer;
the hydrophobic repeat units are characterized in that a homopolymer formed thereof has a glass transition temperature above room temperature;
each of the zwitterionic repeat units independently comprises sulfobetaine, carboxybetaine, phosphorylcholine, or pyridinium alkyl sulfonate;
each of the hydrophobic repeat units independently is formed of styrene, fluorinated styrene, methyl methacrylate, acrylonitrile, or trifluoroethyl methacrylate; and
the polymer fiber is uniformly made from the statistical copolymer.
US Pat. No. 10,709,774

IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS

Enzo Biochem, Inc., New ...

1. A pharmaceutical composition, comprisinga synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2); and
rapamycin.
US Pat. No. 10,709,522

REACTIVE MICRO APPLICATOR WITH METAL-CONTAINING ADDITIVES FOR USE IN DENTAL ADHESIVES

KULZER GMBH, Hanau (DE)

21. Method of affecting the polymerization of a dental material, the method comprising providing at least one additive selected from metals, metal-containing compounds, and organometallic compounds at or on an application aid by contacting the at least one additive to a polymerizable dental adhesive, wherein the at least one additive comprises as the at least one additive catalytically active platinum in form of platinum sponge, wherein the application aid is impregnated, at least in part, with nano-particulate platinum, wherein the nano-particulate platinum has a particle size of less than or equal to 10 nm, and wherein the nano-particulate platinum is platinum sponge.
US Pat. No. 10,711,317

DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS

GEN-PROBE INCORPORATED, ...

1. A detection reaction mixture comprising at least two detection probe oligomers,wherein a first detection probe oligomer comprises (a) a target-specific sequence selected from the group consisting of SEQ ID NO:11, a complement thereof, and an RNA equivalent thereof, and (b) a detectable label that is joined directly or indirectly to the nucleic acid sequence of (a); and
wherein a second detection probe oligomer comprises (a?) a target-specific sequence selected from the group consisting of SEQ ID NO:12, a complement thereof, and an RNA equivalent thereof, and (b?) a detectable label that is joined directly or indirectly to the nucleic acid sequence of (a?).
US Pat. No. 10,709,781

INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS

7 Hills Pharma LLC, Hous...

1. A pharmaceutical composition comprising:one or more integrin activating compounds and one or more checkpoint inhibitors,
wherein the one or more integrin activating compounds promote integrin-ligand interactions and enhance an activity of the one or more checkpoint inhibitors.
US Pat. No. 10,710,038

WATERLESS DECARBOXYLATION

Ardent LLC, Roslindale, ...

1. A waterless decarboxylation device, comprising:a) a sealed container;
b) a heating element which surrounds the sealed container and is configured to heat the sealed container to over 100° C. for over 30 minutes;
c) a foam layer surrounding the sealed container and the heating element;
e) at least one sensor configured to detect the temperature of the heating element;
f) a lid that encloses the container and fluidly seals it from the environment outside of the container; and
g) a circuit board comprising a controller configured to control power to the heating element in response to signals sent from the at least one sensor indicating whether the heating element has exceeded the temperature 100° C., wherein the controller is configured to control power to the heating element to maintain a temperature of the sealed container at 105° C. for 30 to 90 minutes, and wherein the controller is configured to control power to the heating element to so that the temperature detected at the heating element is not above 130° C.
US Pat. No. 10,709,784

METAL CHELATING COMPOSITIONS AND METHODS FOR CONTROLLING THE GROWTH OR ACTIVITIES OF A LIVING CELL OR ORGANISM

CHELATION PARTNERS INCORP...

1. A chelating composition soluble in an aqueous medium for chelating iron, said chelating composition comprising:a carrier material; and
one or more suitable metal binding chemical groups having iron chelating activity affixed to or incorporated into the structure of the carrier material;
wherein the one or more suitable metal binding chemical groups is one or more of carboxyl, hydroxyl, phenol ate, catechol ate, hydroxamate or hydroxypyridinone types;
wherein the carrier material comprises vinylpyrrolidone, styrene or acrylamide;
wherein the chelating composition is formed by a first monomer group comprising a metal binding monomer representing the metal binding chemical group copolymerized with a suitable second monomer group representing the carrier material such that the resulting co-polymer remains soluble in aqueous solution and has iron chelating activity;
wherein the chelating composition has a minimum molecular weight sufficiently large so as not to be normally taken up into the intra-cellular aspects internal to a cell membrane of a living cell and is able to bind iron; and
wherein the chelating composition remains substantially soluble in the aqueous medium with its bound iron in the external cellular environment of the living cell thereby preventing uptake of the bound iron into the intra-cellular aspects internal to the cell membrane of the living cell.
US Pat. No. 10,711,065

ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIA

1. A method of treating bronchopulmonary dysplasia (BPD) in an infant comprising administering to an infant in need of treatment an effective amount of an anti-Flt-1 antibody or antigen fragment thereof, wherein the anti-Flt-1 antibody or antigen fragment thereof comprises:a VL CDR1 defined by the amino acid sequence of SEQ ID NO: 21,
a VL CDR2 defined by the amino acid sequence of SEQ ID NO: 24,
a VL CDR3 defined by the amino acid sequence of SEQ ID NO: 32,
a HL CDR1 defined by the amino acid sequence of SEQ ID NO: 3,
a HL CDR2 defined by the amino acid sequence of SEQ ID NO: 12, and
a HL CDR3 defined by the amino acid sequence of SEQ ID NO: 17.
US Pat. No. 10,712,345

METHODS AND COMPOSITIONS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS

Mor-NuCo Enterprises, Inc...

1. A cell that expresses an antibody that is a single chain variable region ENOX2-specific antibody fusion protein encoded by a DNA sequence of SEQ ID NOS:1 and 2 separated by a linker, wherein the antibody is fused with an alkaline phosphatase or other protein for single-step detection or imaging.
US Pat. No. 10,711,066

ANTI-CANINE PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA ANTIBODY

Elanco US Inc., Greenfie...

1. A monoclonal antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein the amino acid sequence of LCDR1 is given by SEQ ID NO:16, the amino acid sequence of LCDR2 is given by SEQ ID NO: 18, the amino acid sequence of LCDR3 is given by SEQ ID NO: 20, the amino acid sequence of HCDR1 is given by SEQ ID NO: 6, the amino acid sequence of HCDR2 is given by SEQ ID NO: 8, and the amino acid sequence of HCDR3 is given by SEQ ID NO: 10; and wherein the monoclonal antibody binds canine platelet derived growth factor receptor alpha (cPDGFRA).
US Pat. No. 10,711,322

HOT-PRESSED STEEL SHEET MEMBER, METHOD OF MANUFACTURING THE SAME, AND STEEL SHEET FOR HOT PRESSING

NIPPON STEEL CORPORATION,...

1. A steel sheet for hot pressing, comprising:a chemical composition represented by, in mass %:
C: 0.10% to 0.34%;
Si: 0.5% to 2.0%;
Mn: 1.0% to 3.0%;
sol. Al: 0.001% to 1.0% or less;
P: 0.05% or less;
S: 0.01% or less;
N: 0.01% or less;
Ti: 0% to 0.20%;
Nb: 0% to 0.20%;
V: 0% to 0.20%;
Cr: 0% to 1.0%;
Mo: 0% to 1.0%;
Cu: 0% to 1.0%;
Ni: 0% to 1.0%;
Ca: 0% to 0.01%;
Mg: 0% to 0.01%;
REM: 0% to 0.01%;
Zr: 0% to 0.01%;
B: 0% to 0.01%;
Bi: 0% to 0.01%; and
balance: Fe and impurities; and
a steel structure comprising ferrite and cementite, represented, in area %:
a total area ratio of bainite and martensite: 0% to 10%; and
an area ratio of cementite: 1% or more, and
wherein a concentration of Mn in the cementite is 5 mass % or more.
US Pat. No. 10,709,786

CLEAR AQUEOUS SOLUTION

SENJU PHARMACEUTICAL CO.,...

1. An aqueous liquid preparation comprising: (1) (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof, and (2) one benzalkonium chloride or a mixture of benzalkonium chlorides, wherein benzalkonium chloride is represented by the formula:[C6H5CH2N(CH3)2R]Cl
wherein R is an alkyl group having 8-18 carbon atoms, wherein the transmittance of the aqueous liquid preparation at wavelength 600 nm is not less than 98%, and
wherein the one benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 8 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 10 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 12 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 14 carbon atoms,
wherein the one benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 16 carbon atoms,
wherein the mixture of the benzalkonium chlorides has a total concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms, and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, or
wherein the mixture of the benzalkonium chlorides has a total concentration of 0.003 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms, (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and (iii) a third benzalkonium chloride wherein R is an alkyl group having 16 carbon atoms.
US Pat. No. 10,711,067

TREATMENT OF POST-PRANDIAL HYPERINSULINEMIA AND HYPOGLYCEMIA AFTER BARIATRIC SURGERY

XOMA (US) LLC, Emeryvill...

1. A method of treating post-prandial hypoglycemia following bariatric surgery, comprising administering to a subject in need thereof an antibody that is a negative modulator of insulin binding to the insulin receptor and/or insulin action at the insulin receptor in an amount effective to ameliorate post-prandial hypoglycemia, wherein the antibody comprises three heavy chain CDRs set out in SEQ ID NO: 11-13 and three light chain CDRs set out in SEQ ID NO: 26-28.
US Pat. No. 10,711,323

STEEL SHEET, AND PRODUCTION METHOD THEREFOR

JFE Steel Corporation, T...

1. A steel sheet having a composition comprising, in mass %,C: 0.05% or more and 0.20% or less,
Si: 0.60% or more and 1.65% or less,
Mn: 1.8% or more and 3.5% or less,
P: 0.05% or less,
S: 0.005% or less,
Al: 0.08% or less, and
N: 0.0060% or less,
the balance being Fe and inevitable impurities,
the steel sheet having a metallographic structure containing, in terms of an area ratio, ferrite of 25% or more and 65% or less, martensite having iron-based carbides precipitated in the grains thereof of 35% or more and 75% or less, and the balance structure other than the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof of 20% or less (including 0%) in total,
average grain diameters of the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof being respectively 5 ?m or lower, and
a total of concentrations of Si and Mn at interface between the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof being, in terms of an atomic concentration, 5% or more, and
the steel sheet having a tensile strength of 900 MPa or higher.
US Pat. No. 10,709,529

KIT OF PARTS CONTAINING DENTAL MILL BLANK COLOURING SOLUTION

3M Innovative Properties ...

1. A kit of parts for producing a coloured dental article, the kit of parts comprising:a dental mill blank comprising a porous zirconia material;
a colouring solution for colouring the porous zirconia material; and
a set of instructions;
the porous zirconia material comprising:
Zr oxide calculated as ZrO2: from 80 to 97 wt.-%,
Al oxide calculated as Al2O3: from 0 to 0.15 wt.-%,
Y oxide calculated as Y2O3: from 1 to 10 wt.-%, and
Bi oxide calculated as Bi2O3: from 0.01 to 0.2 wt.-%,
the porous zirconia material not comprising Fe calculated as Fe2O3 in an amount of more than 0.01 wt.-%, wt.-% with respect to the weight of the porous zirconia material;
the colouring solution comprising:
solvent(s), and
colouring agent(s) comprising metal ions selected from Tb, Er, Pr, Mn, or combinations thereof,
the colouring solution not comprising Fe ions in an amount of more than 0.01 wt.-%, and
the colouring solution not comprising Bi ions in an amount of more than 0.01 wt.-%, wt.-% with respect to the weight of the colouring solution;
wherein the set of instructions direct a user to apply the colouring solution to at least a portion of the dental mill blank to form the coloured dental article, and
wherein the coloured dental article is fluorescent and producible in more than half of the colours according to the Vita™ Tooth Shade Guide.
US Pat. No. 10,709,787

HYDROGELS OF METHACRYLIC HYALURONIC ACID DERIVATIVES FOR ORAL ENZYME THERAPY IN CELIAC DISEASE

NEMYSIS LIMITED, Dublin ...

1. A composition comprising:at least one exogenous enzyme, said enzyme being selected from the group consisting of prolyl endopeptidase (PEP), endoprotease (EP) and combinations thereof, said enzyme in a concentration between 1 mU/mg and 100 U/mg being entrapped in an HA-EDA-MA hydrogel; and
trehalose in a concentration between 0.1 and 10% w/w with respect to the weight of the HA-EDA-MA hydrogel;
wherein the HA-EDA-MA hydrogel is formed by photocrosslinking HA-EDA-MA derivatives;
wherein the HA-EDA-MA derivatives is formed from hyaluronic acid (HA) or a salt thereof, having a molecular weight between 50,000 and 1,500,000 Daltons, and is formed via activation of at least one hydroxyl group of HA with a carbonating agent chosen between carbonic phenylesters and haloformic phenylesters followed by functionalization of the activated hydroxyl group by reaction with ethylenediamine (EDA) and subsequent reaction with methacrylic anhydride (MA); and wherein the composition is in the form of a freeze dried powder.
US Pat. No. 10,711,068

ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

THE UNITED STATES OF AMER...

1. An anti-CD133 monoclonal antibody having an antibody binding site comprising CDR-H1 comprising residues 44-50, 44-53, 49-53 or 48-53 of SEQ ID NO:9, CDR-H2 comprising residues 70-74, 68-76, 68-83 or 65-76 of SEQ ID NO:9, CDR-H3 comprising residues 114-116 or 112-115 or SEQ ID NO:9, CDR-L1 comprising residues 46-58 or 52-60 of SEQ ID NO:11, CDR-L2 comprising residues 74-80 or 70-79 of SEQ ID NO:11, and CDR-L3 comprising residues 113-125 or 113-124 of SEQ ID NO:11.
US Pat. No. 10,712,348

KISSPEPTIN-54 DETECTION BY TANDEM MASS SPECTROMETRY

Quest Diagnostics Investm...

1. A method for determining by mass spectrometry the amount in a sample of two or more kisspeptin-54-derived peptides, said method comprising:(a) enriching the sample comprising two or more kisspeptin-54-derived peptides selected from the group consisting of kisspeptin-54, kisspeptin-53, kisspeptin-52, kisspeptin-54(R14P), kisspeptin-53(R14P), and kisspeptin-52(R14P) by high turbulence liquid chromatography (HTLC);
(b) ionizing the enriched sample to produce two or more kisspeptin-54-derived peptide ions detectable by mass spectrometry;
(c) determining the amount of two or more ions by mass spectrometry, wherein the amount of the ions is used to determine the amounts of the corresponding two or more kisspeptin-54-derived peptides in the sample.
US Pat. No. 10,709,530

PHOTOCURABLE COMPOSITION, DENTURE BASE, AND PLATE DENTURE

MITSUI CHEMICALS, INC., ...

1. A photocurable composition that is used for production by stereolithography of a dental prosthesis, a medical device for intraoral use, or a tooth and/or jaw model, the photocurable composition comprising:a (meth)acrylic monomer component and a photopolymerization initiator;
wherein the (meth)acrylic monomer component comprises:
an acrylic monomer (X) that is at least one selected from diacrylic monomers containing, within one molecule, two aromatic rings and two acryloyloxy groups, and that has a weight average molecular weight of from 400 to 580; and
at least one selected from the group consisting of:
a (meth)acrylic monomer (A) that is at least one selected from di(meth)acrylic monomers not containing, within one molecule, an aromatic ring and containing, within one molecule, one or more ether bonds and two (meth)acryloyloxy groups, and that has a weight average molecular weight of from 200 to 400;
a (meth)acrylic monomer (B) that is at least one selected from (meth)acrylic monomers not containing, within one molecule, an aromatic ring and containing, within one molecule, a ring structure other than an aromatic ring and one (meth)acryloyloxy group, and that has a weight average molecular weight of from 130 to 240; and
a (meth)acrylic monomer (C) that is at least one selected from di(meth)acrylic monomers not containing, within one molecule, an aromatic ring or an ether bond and containing, within one molecule, a hydrocarbon skeleton and two (meth)acryloyloxy groups, and that has a weight average molecular weight of from 190 to 280, and
wherein the photopolymerization initiator is at least one selected from alkylphenone compounds or acylphosphine oxide compounds.
US Pat. No. 10,711,069

METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FC?RACTIVATING AND FC?RINHIBITING

MacroGenics, Inc., Rockv...

1. A polypeptide comprising a variant Fc region, wherein said variant Fc region is a variant of a human IgG Fc region, and wherein said variant Fc region comprises the following amino acid modifications relative to a wild-type Fc region:(a) L235I, F243L, R292P, Y300L, and P396L;
(b) L235Q, F243L, R292P, Y300L, and P396L;
(c) L235V, F243L, R292P, Y300L, and P396L; or
(d) L235P, F243L, R292P, Y300L, and P396L;
wherein the positions are numbered according to the EU index as in Kabat.
US Pat. No. 10,712,349

CIRCULATING KIM-1 LEVELS FOR DETECTION OF PATHOLOGIES ASSOCIATED WITH INJURY TO, OR CANCER OF, THE KIDNEY

1. An assay for diagnosing kidney injury or Renal Cell Carcinoma (RCC) in a subject and treating the subject, consisting essentially of:a. contacting a blood sample obtained from a subject identified to have, or at risk of having a kidney injury, with an anti-KIM-1 antibody that specifically binds to a KIM-1 polypeptide of (SEQ ID NO: 1), and measuring the binding between the KIM-1 polypeptide and the anti-KIM-1 antibody;
b. comparing the level of the KIM-1 polypeptide in the blood sample with a reference level of the KIM-1 polypeptide;
c. selecting the subject as having a kidney injury or Renal Cell Carcinoma (RCC) when the level of KIM-1 polypeptide in the blood sample is 4-fold higher, or greater than 4-fold higher than the reference level for the KIM-1 polypeptide; and
d. administering an effective treatment for treating kidney disease to the subject selected as being diagnosed with a kidney injury or RCC.